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Abstract 
CDX2 is an intestinal specific transcription factor, which is essential for normal intestinal 
development. CDX2 functions by up-regulating an array of genes during the differentiation 
process and presumably inhibit proliferation of undifferentiated intestinal epithelial cells. 
Lack of CDX2 often leads to increased proliferation and tumorigenesis. CDX2 is part of an 
intestinal transcription factor network which also includes HNF4α. HNF4α is a transcription 
factor which is also involved in intestinal development and cancer development. The growth-
inhibitory Hippo signal pathway prevents the nuclear transport and thus gene regulatory 
activity of the transcriptional co-activator YAP1. YAP1 is widely expressed and facilitates 
the expression of several proliferative and anti-apoptotic genes. It is up-regulated in several 
types of cancer and is generally believed to be a potent oncogene and a possible future cancer 
therapy target. 
Recently published ChIP-seq data from the intestinal cell line Caco-2 revealed that CDX2 and 
HNF4α might bind to the promoter and a downstream regulatory element (DRE) of YAP1. In 
this thesis it was the aim to investigate whether CDX2 and HNF4α can bind to regulatory 
regions in the YAP1 gene and regulate its expression in intestinal cells using Caco-2 cells as a 
model.  
An analysis of Caco-2 ChIP-seq data and other data uploaded to the UCSC genome browser 
revealed that the YAP1 promoter and a DRE of the gene probably contain CDX2 and HNF4α 
binding sites. Subsequent ChIP-qPCR confirmed binding of CDX2 to both regions in vivo; 
however HNF4α was only found to bind to the DRE. In silico analysis using the online 
Transfac MATCH tool indicated three CDX2 binding sites and a possible HNF4α site in the 
promoter region while two CDX2 and an HNF4α site were found in the DRE. Using EMSA it 
was found that CDX2 and HNF4α bind in vitro to the three sites in the DRE. 
Luciferase reporter plasmids containing the YAP1 promoter and DRE regions were 
constructed and transfected into Caco-2 cells with and without CDX2 and HNF4α expression 
plasmids. It was found that the DRE enhanced the reporter gene expression 12-fold and that 
CDX2 overexpression attenuated the DRE effect by 50 % whereas HNF4α overexpression 
enhanced it 3-fold. However, transfecting luciferase reporter plasmids with mutated binding 
sites revealed that all sites in the DRE, but especially the most proximal CDX2 site, were 
contributing to the enhancer effect of the DRE. It was attempted to elucidate this 
contradictory evidence further by sh-RNAi knockdown of CDX2. 
In conclusion, two novel binding sites for CDX2 and one for HNF4α were identified in an 
enhancer in the YAP1 gene. It was established that both transcription factors are important 
regulators of YAP1 expression. Furthermore, CDX2 might be a repressor of YAP1 expression 
while HNF4α is an activator. 
These results reveal that two of the most important regulators (CDX2 and HNF4α) of the 
intestinal differentiation process, also regulates the expression of a key gene in the Hippo 
pathway (YAP1). This discovery assists in clarify the complex regulation patterns that govern 
both intestinal development and tumorigenesis. 
 
 
 
Dansk resumé 
CDX2 er en tarm-specifik transkriptionsfaktor, der er essentiel for normal intestinal 
udvikling. CDX2 fungerer ved at opregulere ekspressionen af en række gener under 
differentieringsprocessen og formentlig nedsætte proliferationen af de umodne tarmepithel-
celler. Mangel på CDX2 medfører ofte øget proliferation og tumordannelse. CDX2 er en del 
af et intestinalt transkriptionsfaktor-netværk, hvori også HNF4α indgår. HNF4α er en 
transkriptionsfaktor, der ligeledes er involveret i intestinal udvikling og cancer udvikling. 
Den vækst-inhibitoriske Hippo signalvej forhindrer den nukleare transport, og derved gen-
regulatoriske aktivitet, af den transkriptionelle co-aktivator, YAP1. YAP1 proteiner er bredt 
udtrykt og faciliterer ekspressionen af adskillige proliferative og anti-apototiske gener. Det er 
opreguleret i flere typer af cancer og bliver generelt betragtet som et potent onkogen og et 
muligt fremtidig mål for cancerbehandling. 
Nyligt publiceret ChIP-seq data fra den intestinale celleline Caco-2 har vist, at CDX2 og 
HNF4α sandsynligvis binder til promoteren og et nedstrøms regulatorisk område (DRE) i 
YAP1. Denne specialerapport har til formål at undersøge om CDX2 og HNF4α kan binde sig 
til regulatoriske områder i YAP1 genet, og derved regulere dettes ekspression i intestinale 
celler, ved at bruge Caco-2 celler som et modelsystem.  
En analyse af Caco-2 ChIP-seq data, samt andet data uploadet til UCSC genom broweren, 
viste at YAP1 promoteren og DRE sandsynligvis indeholder bindingssekvenser for CDX2 og 
HNF4α. Efterfølgende ChIP-qPCR bekræftede binding af CDX2 til begge regioner in vivo 
men fandt kun evidens for HNF4α binding til DRE. In silico analyse ved brug af det online 
værktøj Transfac MATCH afslørede tre potentielle CDX2 bindingsekvenser og én mulig 
HNF4α bindingssekvens i promoterregionen, mens én HNF4α og to CDX2 bindingssekvenser 
blev fundet i DRE. Ved at benytte EMSA var det muligt at bekræfte in vitro binding af CDX2 
og HNF4α til de tre sekvenser i DRE. 
Luciferase reporter plasmider indeholdende YAP1 promoteren og NRO blev konstrueret og 
transfekteret ind i Caco-2 celler enten med eller uden CDX2 og HNF4α 
ekspressionsplasmider. Dette viste at tilstedeværelsen af DRE forøgede reportergen 
expressionen 12-fold og at CDX2 overexpression medførte en inhibering af forøgelsen på ca. 
50 % hvorimod HNF4α overekspression forøgede DRE-effekten ca. 3-fold yderligere. Dog 
viste transfektion af luciferease reporterplasmider med muterede bindingssekvenser at alle 
bindingssekvenserne i DRE, dog i størst grad den proximale CDX2 sekvens, bidrager til 
effekten af ekspressionsforøgelsen fra DRE. Det blev forsøgt at forklare disse modstridende 
data ved hjælp af sh-RNAi knockdown af CDX2. 
Som konklusion blev to nye bindingssekvenser for CDX2 og én for HNF4α identificeret i en 
enhancer i YAP1 genet. Det blev påvist, at begge transkriptionsfaktorer er vigtige regulatorer 
af YAP1 ekspressionen. Endvidere tyder det på at CDX2 er en repressor af YAP1 expressionen 
mens HNF4α er en aktivator. Disse resultater viser, at to af de vigtigste regulatorer (CDX2 og 
HNF4α) af den cellulære differentieringsproces i tarmen også regulerer ekspression af et 
nøgle-gen i Hippo signaleringen (YAP1). Dette fund føjer endnu en brik til de komplekse 
reguleringsmønstre der styrer både intestinal udvilking samt cancer udvikling. 
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1 Aim of the project 
Development of the intestines and tumorigenesis are both processes controlled by a 
regulatory network of transcription factors and signal pathways. Caudal type homeobox 2 
(CDX2) is an intestinal specific transcription factor (TF) which is essential for normal 
intestinal development. It controls the expression of several hydrolytic enzymes expressed in 
the small intestines including sucrase-isomaltase and lactase which both are needed for 
hydrolysis of disaccharides. CDX2 also functions as a switch between cell proliferation and 
differentiation and lack of CDX2 often leads to increased proliferation and tumorigenesis. 
The TF network, which CDX2 is part of, contain several other important TFs, which both 
regulates specific genes and each other. The understanding of this network is still growing, 
but so far it is well established that hepatocyte nuclear factor 4 alpha (HNF4α) and 
hepatocyte nuclear factor 1 (HNF1) both have a central role. HNF4α is not intestinal specific 
but still regulates many of the genes involved in enterocyte differentiation and has also been 
demonstrated to play a role in cancer development. CDX2, HNF4α, and HNF1 all regulate the 
expression of each other in a complex system in intestinal cells. A general hypothesis is that 
CDX2 generally functions as a tumor suppressor and that HNF4α might have either tumor 
suppressor or oncogenic properties depending on the specific circumstances.  
The Hippo pathway is a relatively recent discovered pathway, which is involved in limiting 
organ size and in controlling cellular differentiation and proliferation. It is an inhibitory 
pathway that relays signals from cell-cell contact and other yet unknown size determinants 
through a kinase cascade. The main function of the Hippo pathway is to phosphorylate and 
thus prevent its main effector Yes-associated protein 1 (YAP1) from entering the nucleus. 
YAP1 is a transcriptional co-activator, which is active when located in the nucleus where 
enables other TFs to express specific genes involved in proliferation and anti-apoptosis. 
YAP1 is up-regulated in many colorectal cancers (CRC) and in several other types of cancer. 
It has also been shown that the amount of unphosphorylated nuclear YAP1 is related to tumor 
progression and differentiation levels. The oncogenic property of YAP1 could be due to a 
disrupted or nonfunctional Hippo signaling, but another explanation could be a changed 
expression level of YAP1. Several studies have shown that overexpressing YAP1 in intestinal 
cells leads to increased proliferation and tumorigenesis, and that knock-down has the reverse 
effect. YAP1 is thus generally believed to be a potent oncogene and a possible future cancer 
therapy target. Recently, CDX2- and HNF4-bound chromatin from the colon cancer cell line 
Caco-2 were immunoprecipitated and sequenced (ChIP-seq) and inorder to identify target 
genes of CDX2 and HNF4α. In this data the YAP1 gene contained several binding sites for 
both CDX2 and HNF4α.  
The aim of this thesis is to investigate whether a crosstalk between the intestinal 
transcription factor network and the Hippo pathway exists by investigating whether CDX2 
and/or HNF4α can bind to and regulate YAP1 expression in intestinal cells using the Caco-2 
cells as a model system. It further seeks to identify the specific binding sites and to mutate 
them in order to elucidate their specific effect on YAP1 expression. This will add to the 
understanding of the transcriptional regulation of both intestinal and cancer development. 
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2 Introduction 
2.1 Colon anatomy and function 
Reports have suggested that YAP1 might function as either a tumor suppressor or an 
oncogene depending on the conditions. YAP1 has been implicated in colorectal cancer (CRC) 
development, see paragraph 2.3.2. Both of the transcription factors CDX2 and HNF4α that is 
investigate in this project have been implicated in CRC as well.  This section will briefly go 
through the basics of colon function, anatomy and development to provide an understanding 
of the environment that the TF’s interacts in. 
 
2.1.1 Colon function 
The colon has two primary functions essential for maintaining normal digestion; absorption 
of water and salts, and propulsion of digested food for evacuation. When food is digested in 
the small intestines it is transferred as liquid chime to the colon. The colon extracts the 
majority of water from the digested food along with essential salts. The colon can also 
excrete both water and salts as a way to maintain homeostasis or in response to several 
diseases such as cholera. Both crypt-based and lumen-based colonocytes takes part in 
secretion and excretion. 
Inside the colon a highly populated and diverse community of bacteria thrives in symbiosis. 
They can break down some complex polysaccharides or fibers and also sugars such as lactose, 
which have escaped the small intestines. Several byproducts of the bacterial metabolism are 
vitamins, especially vitamin K and biotin that are absorbed by diffusion. The second function 
of the colon is producing and excreting mucus from its goblet cells. The mucus is necessary 
for a smooth transfer of digested food to the rectum.  
 
2.1.2 Colon anatomy 
The colon is about 1.5-1.8 m in total and begins from the cecum where the ileum and 
appendix is attached. It consists of four parts; the ascending colon is located in the right side 
and travels superiorly into the transverse colon running from right to left side. The transverse 
colon continues into the descending colon which travels inferiorly ending in the sigmoid 
colon (“SEER Training: Anatomy of Colon and Rectum,” 2013). 
The colon consists of four histologically separate layers. The inner layer towards the colon 
lumen is the mucosa, which has cells that performs the primary secretory and absorptive 
functions of the colon. The second layer is the submucosa which is mainly connective tissue 
containing blood, lymph, and nerve endings stimulating secretion. The third layer is 
muscularis which contains the smooth muscle, longitudal muscle fibers, and nerves 
responsible for the peristaltic movements. The fourth and outer layer is a membrane lining the 
colon, commonly referred to as serosa. It is derived from mesoderm, not endoderm like the 
three other layers. Peritoneal organs are covered in standard serosa which is a lubricating 
membrane that helps reduce friction to outside tissue. The transverse colon is located 
peritoneal and is covered in serosa but the ascending, descending, and sigmoid colon are 
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located retroperitoneal and are therefore covered in adventitia wich consists of connective 
tissue which binds tissues together (Hill, 2013). 
The mucosa of the colon is lined with simple columnar epithelium, which is formed into 
tubular glands extending inwards called crypts. These crypts contain three major cell types 
responsible for the main functions of the colon, figure 1 (Humphries & Wright, 2008). The 
most abundant type is the colonocytes which are similar to enterocytes of the small intestines. 
Colonocytes uses both passive and active transporters to absorb water, salts, and vitamin K 
from the liquid digested food entering from the ileus. They are tightly controlling the 
viscosity of the digestion product by Na+/Cl- and H2O transport (Sandle, 1998). Another 
abundant cell type is the mucin secreting goblet cells. Mucin is the main element of the 
mucus that lines the entire colon and facilitates the movement of the digested food.  
 
Figure 1 – Overview of a general human colon crypt. CBCC crypt based columnar cells and/or +4 cells are the 
primary intestinal stem cells in the bottom of the crypt, dividing into progenitor cells. The progenitor cells 
proliferate to shift cells into the colon lumen. Progenitor cells will mainly differentiate into colonocytes which 
controls absoption/excretion of water and salts, or into goblet cells which secrete the mucin that forms the 
protective mucus layer. Image modified from (Medema & Vermeulen, 2011) 
 
The last major type of cells is the intestinal stem cells responsible to the constant renewal of 
the epithelial cells. Currently stem cell researchers are debating the location of the primary 
stem cells, but both the crypt based columnar cells (CBCC) and the +4 cell(s) have been 
suggested, figure 1. Both CBCC and +4 cells has been demonstrated to form the progenitor 
cells that differentiate and migrate from the bottom the crypts and outside into the lumen of 
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the colon (Medema & Vermeulen, 2011). This renewal of cells is necessary due to the high 
turnover of the epithelial cells of about 5-7 days (Frank, 2007). The cells mostly die from 
contact with luminal factors and are exfoliated into the lumen. If they do not die from 
exposure they will undergo apoptosis in situ and subsequent phagocytosis (Gibson, 2004). 
A few cells also work as peptide-secreting endocrine cells but they have not been as well 
characterized as the endocrine cells of the small intestines. 
 
2.2 Colorectal cancer 
Colorectal cancer (CRC) is a term used for cancer in either the colon or the rectum. 
Histologically the colon and rectum are very similar and share the same molecular 
development patterns and tumor progression patterns, which is why they are usually gathered 
in one category. It makes sense to separate them when talking about prognostics and 
treatment. 
In the Nordic countries (Denmark, Sweden, Norway, Finland, Faroe Islands, and Iceland) 
about 16500 people under 75 are diagnosed with CRC each year and a total of 120,000 live 
with the diagnosis. The cumulative risk of getting CRC before age 75 is about 4 % for woman 
and 5 % for men. CRC constitutes about 12 % of the total amount of cancers diagnosed in the 
Nordic countries, which is the third highest cancer incidence rate only exceeded by that of 
breast and prostate cancer (Engholm et al., 2010). It is also one of the more deadly types of 
cancer with more than 7300 deaths each year. 
There are three general ways a tumor can spread in the body; through the vascular system, the 
lymphatic system, or through direct invasion into tissue. Growth of tumors is dependent on 
their ability to dedifferentiate and proliferate without undergoing apoptosis. Metastasis of 
cancers requires that cancer cells can change their surface and extracellular properties to 
influence cell-adhesion and allow transport to non-familiar tissues. These changes often arise 
from mutations in regulatory genes that control the expression of an array of genes. 
 
2.2.1 Staging of colon cancer  
Colon cancer progression begins by proliferation of abnormal or de-differentiated cells in the 
mucosal crypts of the colon. This is called stage 0 or more commonly carcinoma in situ. The 
tumor then begins to grow into and through the tissue layers of the colon, first through the 
submucosa and muscularis, then through the serosa to the lumen of the colon. Depending on 
the progression pattern of the specific tumor, metastasis to lymph nodes and organs can occur 
either before the tumor has invaded the muscularis or after breaking through the serosa to the 
lumen. Correct staging of cancer not only leads to an optimized treatment but also creates a 
uniform background for patient samples used in research. According to the guidelines from 
the National Cancer Institute at the U.S. National Institutes of Health, colon cancer 
progression can be divided into four stages with sub-stages (The National Cancer Institute, 
2013) 
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Stage 0 is normally not referred to as a stage of cancer but rather as carcinoma in situ. It is 
the least progressed form of cancer where abnormal cells are found in but limited to the 
mucosa layer of the colon. 
Stage I describes a situation where cancer cells from the mucosa have spread to the 
submucosa and possible also to the muscularis layer. 
Stage II is diagnosed when the tumor has invaded the muscularis, serosa, or has spread 
through the serosa to the lumen without any spread to lymph nodes. 
Stage III is more complex to diagnose. The primary tumor can have spread to anywhere from 
the submucosa to the lumen, and can possibly also include metastasis to organs, while all 
subtypes includes spreading to lymph nodes. 
 
Stage II, III, and IV are all subdivided to allow a more precise diagnosis. Figure 2 depicts 
diagnosis criteria for stage IIA, IIB, IIC, and IIIA. Figure 3 depicts diagnosis criteria for 
stage IIIB and stage IIIC. 
 
Figure 2 - Colon cancer progression patterns needed for a Stage II diagnosis (left) and Stage IIIA diagnosis (right) 
according to the U.S. National Institute of Health. For stage II diagnosis: “In stage IIA cancer has spread through 
the muscularis to the serosa. In stage IIB cancer has spread through the serosa. In stage IIC cancer has spread 
through the serosa to nearby organs” (The National Cancer Institute, 2013). For stage IIIA diagnosis: “Cancer 
may have spread through the mucosa to the submucosa and muscularis, and has spread to one to three nearby 
lymph nodes or tissues near the lymph nodes. OR, cancer has spread through the mucosa to the submucosa and 
four to six nearby lymph nodes” 
 
Figure 3 - Colon cancer progression patterns needed for a Stage IIIB diagnosis (left) and Stage IIIC diagnosis 
(right) according to the U.S. National Institute of Health. For stage IIIB: “Cancer has spread through the 
muscularis to the serosa or has spread through the serosa; cancer has spread to one to three nearby lymph nodes 
or to tissues near the lymph nodes. OR, cancer has spread to the muscularis or to the serosa, and to four to six 
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nearby lymph nodes. OR, cancer has spread through the mucosa to the submucosa and may have spread to the 
muscularis; cancer has spread to seven or more nearby lymph nodes”. For stage IIIC: “Cancer has spread through 
the serosa; cancer has spread to four to six nearby lymph nodes. OR, cancer has spread through the muscularis to 
the serosa or has spread through the serosa; cancer has spread to seven or more nearby lymph nodes. OR, cancer 
has spread through the serosa to nearby organs and to one or more nearby lymph nodes or to tissues near the 
lymph nodes” (The National Cancer Institute, 2013). 
Stage IV colon cancer is the final and most progressed stage. It can be divided into two 
substages, IVA and IVB. In Stage IV cancer has spread through all layers including the 
serosa and may have spread to either nearby lymph nodes or organs. Simultaneously the 
cancer has spread to one organ or lymph node (IVA) distant to the colon or to several (IVB) 
distant organs or lymph nodes. 
 
2.3 The Hippo signaling pathway 
The Hippo pathway is a regulator of growth and organ size. It was first discovered in 
Drosophila Melanogaster as a growth inhibitory pathway involved in anti-apoptosis and 
tumorigenesis (Edgar, 2006). The pathway consists of a phosphorylation kinase cascade 
ultimately inhibiting the transcription of a wide array of regulatory genes through inactivation 
of the transcription factor YAP1. Mammalian orthologues has recently been identified for 
nearly all components of the pathway and some have been identified as dysregulated in 
several cancer types including colorectal cancer. 
The mammalian Hippo pathway can be divided into two general parts; First upstream 
receptors senses cell-cell contact and other yet unknown organ size indicators and relays the 
information to the Ser/Thr kinases. The kinases then phosphorylate YAP1 and the closely 
related Transcriptional co-activator with PDZ-binding motif (TAZ, also called WWTR1) 
which blocks their entry to the nucleus or results in their ubiquitination and degradation. 
When Hippo signaling is disrupted or missing YAP1 remains unphosphorylated and exerts its 
function by entering the nucleus where it binds to the transcription factor TEA domain family 
member (TEAD) to transcribe an array of genes. YAP1 also targets other transcription 
factors, but TEAD is its main partner. The main role of Hippo signaling is thus to limit the 
transcriptional activity of YAP1 and TEAD through phosphorylation, figure 4. 
7 
 
 
 
Figure 4 – Overview of selected Hippo pathway components with and without active Hippo signaling. A) Active 
Hippo signaling - The receptor MERLIN senses high-cell density and interacts with CD44. This and other yet 
unknown signals cause activation of KIBRA and SAV1. The MERLIN/KIBRA/SAV1 complex phosphorylates 
MST1/2. MST1/2 and SAV1 phosphorylates LATS1/2 and MOB1, which phosphorylates YAP1 at serine-127 and/or 
serine-381. YAP1 Ser-127-P is not shuttled to the nucleus but is retained in the cytoplasm by binding to 14-3-3. 
YAP1 Ser381-P is ubiquitinated by SCFβ-TRCP and subsequently degraded. It can also be retained in the 
cytoplasm by αE-catenin. B) If YAP1 is unphosphorylated because of a lack of Hippo signaling, it can be 
transported to the nucleus and bind to transcription factors such as TEAD to transcribe a multitude of genes, 
including oncogenes, tumor suppressor genes and proliferation/differentiation genes. αE-catenin can bind YAP1 
regardless of Hippo activation and thus still inhibits YAP1 transport to the nucleus. 
 
2.3.1 The core of the Hippo pathway 
The upstream signals to the core of the Hippo pathway have only begun to be elucidated, 
especially in mammals. A recent study found that the receptor MERLIN encoded by the gene 
NF2 (Neurofibromin 2 (merlin)) physically interacts with KIBRA  encoded by the gene WW 
and C2 domain containing 1 (WWC1) and Salvador homolog 1 (SAV1, also called WW45) 
(Zhang et al., 2010). MERLIN is a receptor that mediates cell-cell contact of growth through 
extracellular matrix signals in corporation with the CD44 receptor. At high cell densities 
mucopolysaccharides on the outside of cells cause MERLIN hypo-phosphorylation and 
interaction with the cytoplasmic tail of the transmembrane CD44 (Morrison et al., 2001). 
MERLIN was shown to be required for Hippo signaling in liver tissue of mice (Zhang et al., 
2010). 
The next step is activation of the two homologues serine/threonine kinases Mammalian 
Ste20-like protein kinases 1 and 2 (MST1 and MST2). It is not yet fully understood how the 
kinases of the pathway are activated by the upstream receptors. When activated MST1/MST2 
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binds to the scaffolding protein SAV1. This complex then phosphorylates both the kinases 
Large tumor suppressor kinase 1 and 2 (LATS1/LATS2) and the adaptor protein MOB kinase 
activator 1 (MOB1) (Pantalacci, Tapon, & Léopold, 2003). 
The complex containing LATS1/2 and MOB1 utilizes the PPxY motif of LATS to bind to the 
WW domain of YAP1 and phosphorylate it. LATS can phosphorylate YAP1 on serines that 
are part of the amino acid sequence HxRxxS (Hao, Chun, Cheung, Rashidi, & Yang, 2008). 
YAP1 contains five sequences where serines are phosphorylated, two of which has been 
shown to be important for inhibiting the function of YAP1. When Ser 127 is phosphorylated 
YAP1 is targeted by the protein 14-3-3 and is retained in the cytoplasm (Hao et al., 2008; 
Oka, Mazack, & Sudol, 2008). This correlates well with the finding that YAP1 Ser-127 
phosphorylation increases with cell density (Zhao et al., 2007). Cytoplasmic retention of 
YAP1 is also mediated by α epithelial catenin (αE-catenin) by physical interaction with 
YAP1 (Silvis et al., 2011). Instead of controlling YAP1 spatially, phosphorylation of Ser-381 
leads to ubiquitination of YAP1 by β–Transducin repeat-containing proteins (β-TRCP) E3 
ubiquitin ligase and subsequent degradation (Zhao, Li, Tumaneng, Wang, & Guan, 2010). 
 
2.3.2 YAP1 
Research has revealed a diverse and perhaps multifunctional role of YAP1 in the Hippo 
pathway as well as outside. It is becoming clearer that YAP1 can both serve as a 
proliferation/differentiation switch and that it helps assign specificity to other transcription 
factors. This paragraph seeks to elaborate on the current understanding of how YAP1 exerts 
its function and how the activity of YAP1 is controlled. 
 
Structure of YAP1 
YAP1 is a transcriptional co-activator functioning as the main downstream effector of the 
Hippo signal pathway. It is also known by the names YAP, YAP2 and YAP65 in the literature 
and was first identified in humans in 1994 (Sudol, 1994). The gene encoding YAP is located 
on chromosome 11q22.1-q22.2 in humans and encompasses 122,818bp, according to the 
USCS genome browser using assembly NCBI36/hg18 of the human genome. The YAP1 
protein has at least 8 different isoforms in humans, of which isoform 1 is the consensus 
sequence used by NCBI (accession AAH38235). It is expressed in many human tissues 
including a relatively high expression in the colon (Gaffney et al., 2012). Isoform 1 contains 
504 amino acids and several well-conserved domains. In literature it is common to see 
isoform 2 used, which contains a deletion of the 16 aa at pos 328-343 in the transactivating 
domain, making the protein 488 aa in total. The function of YAP1 is mainly determined by its 
domains. It contains a proline rich region at the N-terminus followed by a TEAD binding 
domain, two WW domains, an SH3 (Src homology 3) domain, a transactivating domain and a 
Post-synaptic density, Discs large, Zonula occludens-1 (PDZ) binding motif at the C-
terminus, figure 5. 
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Figure 5 – General domains of YAP1 isoform 1 (NCBI, accession AAH38235). At the N-terminal there is a proline 
rich area containing several binding sequences for interacting proteins. The TEAD binding domain is responsible 
for tethering YAP1 to its transcriptional co-activator TEAD in the nucleus. The two WW-domains binds PPxY 
sequences and are essential for YAP1 function. SH3 domains bind a PxxP sequence. The transactivating domain 
Binds to DNA and thus facilitates transcription of YAP1 target genes. The PDZ binding motif is important for 
YAP1 localization and P73 activation and might bind scaffold or transport proteins. Serine 127 and 397 are 
important phosphorylation targets for controlling YAP1 localization or degradation respectively.  
 
YAP1 is transported to the nucleus 
YAP1 is shuttled between the cytoplasm and nucleus by mechanisms not yet fully understood. 
So far it has been demonstrated that both the PDZ binding motif and a motif in the TEAD 
interacting domain containing serine 127 is involved. As mentioned, LATS1 binds to YAP1 
and phosphorylates serine 127. This phosphorylation enables further phosphorylation by the 
14-3-3 protein which inhibits YAP1 nuclear translocation. To investigate this mechanism 
further, a YAP1 S127A mutant was created by substituting serine 127 with alanine. This 
YAP1 mutant is unable to be phosphorylated and is therefore not targeted by 14-3-3 protein 
for further phosphorylation and retention in the cytosol. YAP1 can thus freely interact with 
transporters and translocate to the nucleus where it is found almost exclusively (Oka et al., 
2008). 
The PDZ binding motif is frequently found in scaffolding proteins responsible for shuttling 
proteins to specific cell-compartments (Ye & Zhang, 2013). It has been demonstrated that the 
PDZ motif of YAP1 is essential for the transport of YAP1 to the nucleus. Even when using 
the 127A form of YAP1, removal of the PDZ motif still completely blocks nuclear transport, 
indicating that at least one PDZ binding protein is responsible for YAP1 translocation (Oka & 
Sudol, 2009). That hypothesis was shown to be correct, as the group later identified Tight 
Junction Protein 2 as a PDZ binding protein able to bind and transport YAP1 to the nucleus 
(Oka et al., 2010). 
In addition to the mentioned transporter, YAP1 translocation might be facilitated through the 
WW domains. WW domains are sequences containing a specific motif surrounding two 
tryptophan residues. They are able to bind proline rich sequences found on many proteins, 
specifically PPxY (Nguyen, Turck, Cohen, Zuckermann, & Lim, 1998). It was shown that 
YAP1 physically and functionally interacts with a PPxY domain on the Epidermal growth 
factor receptor 4 (EGFR-4) (Komuro, Nagai, Navin, & Sudol, 2003). EGFR-4 is a 
transmembrane tyrosine receptor kinase which on activation is cleaved and transported into 
the nucleus where it acts as a transcription factor for proliferative genes (Ni, Murphy, Golde, 
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& Carpenter, 2001). The interaction between YAP1 and EGFR-4 is essential for the 
transcriptional activity of EGFR-4, and they are co-localized both in the cytoplasm and 
nucleus (Komuro et al., 2003). This could indicate a common transport mechanism mediated 
by YAP1 and EGFR-4 interaction. 
 
YAP1 as a tumor suppressor 
The role of YAP1 is becoming increasingly complex, and even though it is generally thought 
of as an oncoprotein, several studies have demonstrated different tumor suppressor 
capabilities as well. 
It has been demonstrated that YAP1 can bind to the PPxY motif of the pro-apoptotic p53-
familiy member p73, using its WW domain. It was also shown that overexpression of YAP1 
increases the transcriptional activity of p73 (Strano et al., 2001). When DNA damage is 
detected, P73 is recruited to anti-apoptotic factors together with E1A binding protein p300 
(EP300, also known as p300) and YAP1. P73 is closely related to p53 and can activate 
several of the same genes involved in apoptosis or cell cycle arrest. YAP1 facilitates 
acetylation of p73 and potentiates the recruitment of EP300 eventually leading to apoptosis. 
Furthermore YAP1 enables target specificity of p73 due to its transcriptional coactivation of 
specific promoters (Strano et al., 2005). One example of target specificity involves the SH3 
domain of YAP1. SH3 domains bind with a weak affinity to proline rich sequences, 
specifically a PxxP sequence (Nguyen et al., 1998). The SH3 domain of YAP1 binds a non-
tyrosine receptor kinase called HCK which interacts with p73 to control gene expression. 
When YAP1 is knocked down, HCK- and p73-mediated activation and expression of IPAF, a 
p53/p73 apoptosis factor is significantly reduced (Paliwal, Radha, & Swarup, 2007).  
YAP1 also facilitate p73-mediated apoptosis by competing for the PPxY site with the E3 
ubiquitin ligase Itch. When YAP1 is knocked down by siRNA, p73 protein is significantly 
lower due to Itch-mediated p73 ubiquitination and subsequent degradation (Levy, 
Adamovich, Reuven, & Shaul, 2007). 
 
Oncogenic properties of YAP1 
An immunohistochemical screen of tissue samples from patients suffering from the most 
common malignant tumor types revealed that colonic adenocarcinoma, lung adenocarcinoma, 
and ovarian serous cystadenocarcinoma all had an increased nuclear and cytoplasmic 
expression of YAP1 compared to normal tissue (Steinhardt et al., 2008). A study on cancer 
patients demonstrated that the mRNA and protein levels of YAP1 was higher in both 
hepatocellular carcinoma (HCC) and CRC tumor samples than in normal tissue 
(Tschaharganeh et al., 2013). The expression of YAP1 was also found significantly increased 
in HCC and prostate cancer samples when compared to normal liver tissue. A shift of YAP1 
to nuclear localization was observed along with the increase in expression, indicating that 
YAP1 becomes more active in HCC and prostate cancer cells (Zhao et al., 2007). YAP1 is 
also upregulated in several other types of cancer and it has been demonstrated that the YAP1 
gene expression is amplified in at least three cancer types. The overexpression and nuclear 
localization of YAP1 has also been correlated with a poor diagnosis of intestinal-type gastric 
11 
 
 
cancer patients (Song, Cheong, Kim, Noh, & Kim, 2012). These findings suggest that YAP1 
is an integral part of tumorigenesis is several types of cancer, including CRC cancer. 
 
Furthermore it was also found that YAP1 most likely plays a role in the metastatic process by 
its indirect connection with proteins of the extracellular matrix (ECM). Changes in ECM 
properties and/or composition are typically found in metastasizing cancers. A study has found 
that the transcriptional activity of YAP1 is influenced by both the ECM stiffness and tension. 
In addition the study revealed that experimentally changing the YAP1 protein levels could 
force cells to undergo structural changes that overrule the mechanical inputs. Interestingly 
this effect was shown to be independent of the core Hippo pathway components such as 
LATS kinases and the NF2 receptor and thus represents a secondary mechanism of YAP1 
signal transduction dependent on the GTPase Rho and other yet unknown factors (Lamar et 
al., 2012). 
 
2.3.3 Interaction between the Hippo pathway and other developmental pathways 
As we gain more knowledge about cell signaling it has become apparent that most pathways 
are interconnected functionally and physically and that they form complex regulatory 
networks. Even though the Hippo pathway is a relatively recent discovery in mammals it has 
been shown to interact with several other known signal pathways. These discoveries connect 
the Hippo pathway to other established pathways such as NOTCH, WNT, and TGF-β.  
 
There are several ways in which pathways can interact and affect each other. One possible 
interaction can occur when a pathway regulates the transcription, or degradation of ligands or 
essential components of another pathway. It is also possible that physical interactions 
between components can regulate activity or localization by protein modification or complex 
formation. A third option is having a common component which is important for both 
pathways and therefore has to be shared in a competitive way. Attisano et al. discusses 
several specific examples of signal pathways which interact using the mentioned methods 
(Attisano & Wrana, 2013).  
The TGF-β pathway is important for controlling cell proliferation, differentiation and in 
inducing apoptosis. It has been demonstrated that the YAP1 paralog TAZ, and most likely 
also YAP1, interacts with several transcriptional activators called Smads. Cytosolic TAZ and 
YAP1 bind to Smads and inhibit their nuclear localization and thus function. Both YAP1 and 
TAZ also interacts with Smads in the nucleus, but interestingly this facilitates gene 
transcription instead of blocking function of the Smads (Attisano & Wrana, 2013), figure 6. 
The canonical WNT pathway relays information necessary for embryonic development, 
proliferation, and cell migration through surface receptors to a protein called disheveled. This 
leads to accumulation of the transcriptional activator β-catenin in the nucleus. The Hippo 
pathway converges with WNT signaling on several levels. Active Hippo signaling leads to 
cytoplasmic phosphorylated YAP1/TAZ, which binds β-catenin and prevents it from being 
translocated to the nucleus, thereby blocking WNT specific transcription (Imajo, Miyatake, 
Iimura, Miyamoto, & Nishida, 2012). Another example of Hippo converging with WNT 
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signaling involves cardiomyocytes. Inactive Hippo leads to unphosphorylated YAP1/TAZ 
entering the nucleus. Interestingly, like it is the case with Smads, also β-catenin interacts 
with unphosphorylated YAP1/TAZ in the nucleus. This nuclear interaction have been shown 
to increase transcription of several growth-enhancing genes, leading to mice with an enlarged 
heart (Heallen et al., 2011) , figure 6. 
 
Figure 6 – Simple model for the interaction between the Hippo pathway, TGFβ, and WNT signaling. When 
activated by extracellular signals TGFβ and WNT activate Smads and β-catenin, respectively. Cytoplasmic YAP1 
and its paralogue TAZ inhibit the nuclear localization of both Smads and β-catenin. Nuclear YAP1/TAZ on the 
other hand can interact with both molecules and the transcription factor TEAD to start gene expression. Any of 
the three transcription factors can associate with TEAD alone or in pairs to elicit specific gene expression. Figure 
modified from (Attisano & Wrana, 2013). 
 
The NOTCH pathway is used by cells to communicate to other nearby cells through a 
receptor/ligand system. It controls a large array of functions, but is generally thought to be 
important in differentiation processes and for proliferation. The NOTCH receptor can bind 
the ligands JAGGED and DELTA-LIKE, leading to proteolytic cleavage of the receptor by a 
protein called γ-secretase. The Notch intracellular domain (NCID) is imported to the nucleus 
where it mainly interacts with the transcription factor complex CSL transcribing a multitude 
of genes. Several studies have demonstrated an interaction between the Hippo pathway and 
NOTCH signaling. In MST1/2-deficient mice where Hippo signaling is severely suppressed, a 
nuclear increase of YAP1 and NCID was observed. Simultaneously several NOTCH specific 
genes was also upregulated, especially in the large intestines of the mice. The same study also 
found that the mechanism of increased NOTCH signaling was a result of a YAP1 induced 
increase in expression of the NOTCH ligand JAG-1, a JAGGED homologue (Zhou et al., 
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2011). Another study using cell models confirmed that YAP1 stimulates expression of JAG-1 
dependent on MST1/2 and TEAD4, figure 7. These studies suggest a strong relationship 
between NOTCH and Hippo signaling. 
 
Figure 7 – Model of YAP1 induced NOTCH activation. Hippo signaling mediated by the kinases MST1/2 inhibits 
YAP1 from entering the nucleus by phosphorylation. If MST1/2 is not activated, YAP1 will be transported to the 
nucleus where it will interact with the transcription factor TEAD4. The YAP1-TEAD4 complex will facilitate 
expression of JAG-1, a NOTCH ligand. JAG-1 will exit the cell and bind to nearby NOTCH receptors. 
Also the hedgehog pathway seems to connect with the Hippo pathway. Sonic hedgehog, an 
important ligand in the hedgehog pathway that determines cell organization and formation of 
specialized structures, was demonstrated to induce YAP expression and nuclear localization 
in medulloblastoma cells (Fernandez-L et al., 2009) 
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2.4 Caco2 as a cell model 
In this thesis Caco-2 cells are used as a model for intestinal tumor cells expressing CDX2, 
HNF4α, and YAP1. The Caco-2 cell line is derived from cells in a colon adenocarcinoma 
tumor almost 40 years ago (Fogh & Trempe, 1975). When Caco-2 cells are cultured in vitro 
they grow as a monolayer. After reaching confluence they begin to differentiate and 
morphologically and functionally resemble small intestine enterocytes. The cells are fully 
differentiated about three weeks after confluence. This characteristic is unique for Caco-2 
cells among the intestinal cell lines and makes them interesting for research of the 
transcriptional regulation of the differentiation process. The differentiated cells are not 
completely similar to the small intestinal epithelium. When they differentiate they exhibit 
several features resembling different types of tissues, making Caco-2 cells difficult to 
categorize as either small intestinal or colon cells. Late in the differentiation process they 
have formed microvilli, which are normally present in the small intestines. They do express 
several of the important small intestinal digestive enzymes such as Sucrase-isomaltase, 
lactase, and alanyl aminopeptidase (Hauri, Sterchi, Bienz, Fransen, & Marxer, 1985). They 
also retain several epithelial transport functions of the small intestinal epithelium (Hidalgo, 
Raub, & Borchardt, 1989). This has encouraged research of drug function and transport over 
intestinal epithelial cells using the Caco-2 cell line as a model (Ahlin et al., 2009; Hubatsch, 
Ragnarsson, & Artursson, 2007). Although they were found to lack the mucus layer normally 
present in both the colon and small intestines. It has also been observed that Caco-2 cells 
form a very tight cell-layer similar to those of colon epithelial cells they are derived from (C. 
Wang & Qiu, 2005). Because Caco-2 cells are able to spontaneously differentiate and develop 
features present in both the colon and small intestines it is not a perfect model system for 
either tissue. When fully differentiated and confluent Caco-2 cells are grown for several days 
without splitting they can form dome-like structures with multiple layers of cells. This 
property resembles a cancer-like property of a distorted proliferation and/or differentiation 
pattern. It is not known how these unique properties of Caco-2 cells originated, but perhaps 
they could be a function of de-differentiation in the original tumor or be due to the cells 
originating from a progenitor cell source in the crypts. Caco-2 cells have been used as an 
intestinal cell model for many years and have been shown to express and utilize the same 
main signal pathways and transcriptional regulatory networks as found in vivo. 
Caco-2 cells resemble intestinal cells in their differentiation process, which can be attributed 
to changes in TF levels and in activity of developmental signal pathways. Even though Caco-
2 cells are not derived from the small intestines, and do not form crypts when growing, their 
differentiation process is very similar. As cells differentiate in the small intestines the WNT 
signaling activity decreases while CDX2 expression increase, figure 8. HNF4α expression is 
also low in undifferentiated cells, like progenitor cells and stem cells, but increases to a 
constant high level in differentiated cells, reviewed in (Olsen, Boyd, Danielsen, & Troelsen, 
2012).  
15 
 
 
 
Figure 8 – overview of the CDX2 and HNF4α expression levels and the WNT activity along the small intestinal 
crypt-villus development. WNT activity is high in stem cells and progenitor cells and decreases as cells 
differentiate. In the proliferating cells, decrease in WNT is accompanied by an increase in CDX2 levels. HNF4α 
expression is detected alongside CDX2 expression, but remains more constant while CDX2 increases. Figure 
modified from (Olsen et al., 2012) 
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2.5 CDX2 and HNF4α are essential intestinal transcription factors 
2.5.1 CDX2 
In the previous paragraphs YAP1 has been shown to have a crucial role in facilitating 
extracellular and intracellular inputs to control proliferation and differentiation patterns in 
cells. YAP1 also plays a role in CRC development and might be regulated by Caudal type 
homeobox 2 (CDX2). This paragraph will briefly explain what CDX2 is and why it is 
believed to be a tumor suppressor. 
CDX-2 was first discovered in mice in 1991 (James & Kazenwadel, 1991). It is 313 aa long 
and specifically expressed in the epithelial cells of intestines in adults, and is considered an 
intestinal-specific transcription factor essential for normal differentiation of intestinal cells 
(Suh & Traber, 1996). CDX2 is an integral part of a regulatory network controlling intestinal 
development where CDX2, HNF1α, and HNF4α regulate the expression of each other, 
reviewed in (Olsen et al., 2012). It was also found that CDX2 and HNF1α can interact on the 
protein level to facilitate expression of the lactase gene (Mitchelmore, Troelsen, Spodsberg, 
Sjöström, & Norén, 2000). 
CDX2 takes part in regulating the transition between intestinal differentiation and 
proliferation. It has been demonstrated that CDX2 can be inhibited by the Mitogen-activated 
protein kinase (MAPK) pathway. The function of CDX2 is inhibited by MAPK 
phosphorylation of the serine in position 60 in proliferating intestinal cells whereas in 
differentiating cells CDX2 is mainly unphosphorylated leading to an active gene expression 
(Rings et al., 2001). Several studies have clarified and cemented the role of CDX2 as a switch 
between differentiation and proliferation by establishing the regulation pattern of 
differentiation-specific genes such as sucrase-isomaltase, AMP-activated protein kinase, 
carbonic anhydrase 1, and lactase, reviewed in (Olsen et al., 2012). One of the main functions 
of CDX2 is thus to induce differentiation and inhibit proliferation. 
Several findings have led to the hypothesis that CDX2 has tumor suppressor capabilities. 
Overexpression of CDX2 in an undifferentiated intestinal cell line resulted in arrest of 
proliferation and increased differentiation. It was also found that mice heterozygote for a 
CDX2 mutation develops tumor-like growths of the intestines and when treated with a 
carcinogen were more susceptible for tumors (Bonhomme et al., 2003; Chawengsaksophak, 
James, Hammond, Köntgen, & Beck, 1997). Further support for the tumor supressor 
hypothesis comes from examination of tissue from colorectal cancer patients.  
Immunostaining of CDX2 revealed that late stage colorectal adenocarcinomas were more 
likely to have lost CDX2 expression than early stages, revealing an inverse correlation 
between CDX2 expression and tumor progression. CRC tumors with a high grade of 
differentiation also generally showed a lower level of CDX2 than tumors with a low 
differentiation (Bakaris, Cetinkaya, Ezberci, & Ekerbicer, 2008; Choi et al., 2006). 
These findings indicate that CDX2 expression and regulation generally is lowered along with 
tumor progression. This would in turn lead to a changed expression pattern of CDX2 
regulated genes.  
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2.5.2 HNF4α 
Hepatocyte nuclear factor 4 alpha (HNF4α) is a transcription factor discovered in 1989 
(Costa, Grayson, & Darnell, 1989). HNF4α is expressed in kidney, pancreas, small intestine, 
testis, colon, and liver tissue (Drewes, Senkel, Holewa, & Ryffel, 1996). HNF4α has at least 9 
different isoforms, of which HNF4α1–3 are derived from the P1 promoter and HNF4α7–12 
from the P2 promoter. The P2 promoter derived isoforms lack 16-29 amino acids in the N-
terminal region (“Bolotin et al.,” 2012). Both P1 and P2 derived isoforms are expressed in the 
colon, but only P1 derived isoforms are found in the liver and kidneys (Tanaka et al., 2006). 
HNF4α is essential for crypt formation in the colon and important for development of both 
the intestinal and the hepatic epithelium (Garrison et al., 2006). HNF4α has an important part 
of a regulatory network controlling intestinal development. The network contains other 
intestinal transcription factors such as CDX2, HNF1, and GATA6. It was also demonstrated 
that most of the genes that are up-regulated in the differentiation process of enterocytes have 
HNF4α binding sites (Boyd, Bressendorff, Møller, Olsen, & Troelsen, 2009). Another study 
has also revealed a role for HNF4α in immune response. It showed that the complement factor 
C3, which is involved in innate immunity and metabolic processes, is under positive 
transcriptional regulation by HNF4α in hepatic cancer cells (Shavva et al., 2013). Another 
study demonstrated that HNF4α is involved in the gluconeogenesis in Caco-2 cells by 
inducing the expression of the key enzyme glucose-6-phosphatase (Gautier-Stein, Zitoun, 
Lalli, Mithieux, & Rajas, 2006). Several other metabolic enzymes and digestive brush border 
enzymes is regulated by HNF4α, reviewed in (Olsen et al., 2012). 
HNF4α has been known to controls the expression of many differentiation specific genes and 
simultaneously it is part of a regulatory network with several developmental transcription 
factors. Even so, the research on HNF4α in cancer development is relatively new and sparse. 
One study suggests that HNF4α has a tumor suppressor role in development of HCC in 
mammals. They found that decreased HNF4α levels induced proliferation, dedifferentiation, 
and metastasis of HCC patients and that restoring the HNF4α expression partially rescued the 
phenotype. They also found a loss or significant decrease of HNF4α levels in about 70 % of 
human HCC samples (Lazarevich et al., 2010). Another study investigated P1 and P2 
promoter specific HNF4α isoforms in CRC patient samples. It concluded that P1 derived 
isoform expression was lost in over 40% of cases, but P2 was normal. P1 derived HNF4α loss 
was demonstrably correlated with depth of tumor invasion, lower survival rate, and more 
liver metastasis (Oshima et al., 2007). These findings suggest a tumor suppressor role for 
HNF4α, but only a few other similar studies have been carried out characterizing its function 
in cancer development, reviewed in (Chellappa, Robertson, & Sladek, 2012). 
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2.5.3 CDX2, HNF4α and YAP1 
It is clear that CDX2, HNF4α, and YAP1 functions as key regulators in intestinal 
development and that they also have a function in cancer development. Not only do they 
share similar functions, but they have been shown to directly regulate each other. This 
paragraph aims to describe the connection between all three factors, figure 9. 
 
 
Figure 9 – model of the transcriptional regulation of CDX2 and HNF4α in intestinal cells and their possible 
regulation of YAP1. CDX2 autoregulates its expression by binding to its own promoter and to a downstream 
enhancer element. CDX2 also regulates HNF4α expression by direct interaction. HNF4α is also able to positively 
regulate the expression of CDX2. YAP1 might be either positively or negatively regulated by both CDX2 and 
HNF4α.  
 
CDX2 can auto regulate its expression by binding to its promoter and a downstream enhancer 
(Boyd et al., 2009; Xu, 1999). A study done in cells and mice models concluded that HNF4α 
is also able to regulate CDX2 expression (Benahmed et al., 2008). Recently Saandi et al. 
investigated both CDX2 and HNF4α in CRC models to determine their roles. In three separate 
mice models a decreased expression of both CDX2 and HNF4α was found in malignant 
intestinal cells. It was also discovered that both the expression level and protein level of 
HNF4α followed that of CDX2. They also found that overexpressing HNF4α in Caco-2 cells 
increased CDX2 levels accordingly, while HNF4α knockdown also lowered CDX2 expression 
(Saandi et al., 2013). These experiments demonstrate the close regulatory relationship 
between HNF4α and CDX2 in intestinal cells. 
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3 Materials and Methods 
 
3.1 Reporter plasmid construction and In-Fusion cloning 
3.1.1 An overview of the In-Fusion cloning process 
PCR primers were designed with the online tool primer3 (Untergasser et al., 2012) to amplify 
the YAP1 promoter, see table 1. Primers were ordered from MWG Eurofins used to PCR 
amplify the promoter sequence. Secondly the Clontech online converter (“Clontech,” 2013) 
was used to design a primer-tail of 16 specific nucleotides that makes the insert partly 
complementary to the expression vector pGL4.10 and to introduce a specific restriction site 
around the insert. The In-Fusion primers were used to PCR amplify the promoter insert, 
adding the tails. pGL4.10 was prepared by digestion with HindIII, and the cloning was 
carried out using the In-Fusion HD cloning kit (Clontech, Cat#639649). This YAP1 promoter 
clone was used as vector for the DRE cloning, using the SalI restriction site. 
A flowchart presenting an overview of the In-Fusion cloning process is seen on figure 10. 
Table 1 – Primers used for PCR amplification of inserts and for In-Fusion cloning 
Primer 
name 
Primer sequence Restriction 
Site 
Promoter F CCGTTTACCCCTCTCAAGTG  
Promoter R GCTGTCCTCGCTCTCAGG  
In-Fusion 
Promoter F 
CTCGGCGGCCAAGCTTCCGTTTACCCCTCTCAAGTG HindIII 
In-Fusion 
Promoter R 
CCGGATTGCCAAGCTTGCTGTCCTCGCTCTCAGG HindIII 
DRE F TGACTGGATTAGACTGGATGCT  
DRE R GGAAAAAGAAAATGTAGTGAGAGC  
In-Fusion 
DRE F 
ATAAGGATCCGTCGACTGACTGGATTAGACTGGATGCT Sal1 
In-Fusion 
DRE R 
AAGGGCATCGGTCGACGGAAAAAGAAAATGTAGTGAGAGC SalI 
The underlined sequences represent the added nucleotides necessary for In-Fusion cloning of the inserts into the 
pGL4.10 expression vector. The boxed-in sequence represents the restriction sites introduced on each site of the 
insert. 
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Figure 10 – Flowchart describing the process of cloning the YAP1 promoter and downstream regulatory element 
into the expression vector pGL4.10 using In-Fusion cloning. In step 1 the YAP1 promoter and downstream 
regulatory element (DRE) are PCR amplified. In step 2 a second PCR is performed on the template from step 1 
using In-Fusion primers, attaching tails to the inserts for cloning. Step 3 is the In-Fusion cloning of the inserts 
from step 2 and the digested vector plasmid. The pGL4.10-promoter construct is digested and the DRE inserted by 
a second In-Fusion cloning. 
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Preparing inserts 
The YAP1 promoter sequence was amplified by Touch-Down PCR, using Advantage- GC 
polymerase and GC-Melt (Clontech, #639112) according to manufacturer’s protocol, using 
“In-Fusion Promoter F” and “In-Fusion Promoter R”, table 1. The DRE was PCR amplified 
using the Phusion Hot Start II polymerase (New England biolabs, #M0530L) according to the 
manufacturer’s protocol, using “In-Fusion DRE F” and “In-Fusion DRE R”, table 1. 
Amplifications were carried out on a 96-well Veriti Thermal Cycler (Applied biosystems, 
#603666). 
PCR products were run on a 1% agarose gel and subsequently purified using Quick Gel 
Extraction Kit (Qiagen, #28704).  
 
Preparing the vector 
2 µg pGL4.10 vector was digested with 10U HindIII (Thermo Scientific, #ER0501) for 2 hrs 
at 37°C. The digestion product was run on a 1% agarose and purified using Quick Gel 
Extraction Kit (Qiagen, #28704).  
For construction of the pGL4.10-promoter+DRE plasmid, 2 µg pGL4.10-promoter plasmid 
was digested with 10U SalI (New England Biolabs, # R0138S) and purified using the same 
procedure. 
 
In-Fusion cloning and transformation 
50 ng purified linearized pGL4.10-vectors were mixed with 25ng purified promoter/DRE 
insert, In-fusion HD enzyme premix, and dH2O. The reaction was incubated 15min at 50°C 
and placed on ice. 2.5µl of the transformation reaction was transferred to 25 µl One Shot 
TOP10 chemically competent E. coli cells (Invitrogen, #C4040-03) and was incubated on ice 
30 min. The cells were then heatshocked for 45 sec at 42°C in water and subsequently cooled 
on ice 2 min. 250 µl S.O.C medium (Invitrogen, #15544-034) was added and reactions were 
incubated at 37°C with horizontal shaking for 1 hr. 100µl was then plated on pre-heated LB 
agar plates containing 100 µg/ml ampicillin. Plates were incubated at 37°C overnight. 
 
Construction of reporter constructs with mutated binding sites 
Inserts with mutated binding sites were created by PCR amplifying forward primers 
containing mutated binding sites, with reverse primers containing In-fusion tails and vice 
versa.  They were subsequently combined in a third PCR amplification. Example for the first 
CDX2 site mutation: “In-Fusion DRE R” and the forward “YAP1-CDXM1” was amplified 
using the protocol for the DRE. Then the “In-Fusion DRE F” and the reverse “YAP1-
CDXM1” were amplified. The two PCR products was mixed, PCR amplified, and gel 
purified. Mutated inserts were In-Fusion cloned and transformed like the standard expression 
plasmids. Single colonies were used to make plasmid preparations. 1µg plasmid was digested 
for 60 min at 37°C with 20U of either PstI (New England Biolabs, #R0140S), XhoI (New 
England Biolabs, #R0146S) or XbaI (New England Biolabs, #R0145S) with 1 µL reaction 
buffer (New England Biolabs, #B7204S). The digestion products was run on a gel to select 
for plasmids with mutated inserts. 
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Plasmid preparation and sequencing 
The following day six colonies were selected for plasmid preparation. Each colony was 
transferred to 30ml LB media containing 100 µg/ml ampicillin and incubated overnight at 
37°C.  Plasmids were purified from the overnight culture by using PureLink Quick Plasmid 
Miniprep Kit (Invitrogen, # K2100-11) and eluted in TE buffer. Sequencing was done by mail 
order by Beckman Coulter Genomics. 
3.2 Short hairpin RNA knockdown by lentiviral delivery 
shRNA targeting CDX2 or a scrambled sequence was transduced into 80 % confluent 
undifferentiated Caco-2 cells by using the lentiviral vector pLKO.1 with a U6 promoter. The 
transduced cells were selected by 25 µg/ml puromycin (Invitrogen, #A11138-03) treatment 
and were grown for one week before harvested for RNA extraction. The shRNA was targeted 
at the second exon in CDX2, Table 2. The transduced Caco-2 cells were kindly provided by 
Ph.d-stud Steffen Jørgensen. RNA was extracted using the RNA isolation procedure included 
with the TRIzol reagent (Invitrogen, #15596-026) 
Table 2 – Target sequences for lentiviral shRNA knockdown of CDX2 in Caco-2 cells 
Target shRNA hairpin sequence 
CDX2 CCGGCAAATATCGAGTGGTGTACACCTCGAGGTGTACACCACTCGATAT
TTGTTTTTG 
Scrambled CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG 
The underlined nucleotides in the table are the target sequence of the shRNA. 
3.2.1 Cultivating Caco-2 and HEK293 cells 
Human colon adenocarcinoma (Caco-2) cells and Human Embryonic Kidney 293 (HEK293) 
cells were grown in T175 culture flasks (Nunc, cat#159910) in Dulbecco's Modified Eagle 
Medium (DMEM, Lonza, cat#BE12-604F-U1), added 10% Fetal Bovine Serum gold (FBS, 
PAA, cat#A15-151) and added 10 mL Antibiotic Antimycotic Solution(SigmaAldrich, 
cat#A5955). The cells were incubated at 37 °C in 5 % CO2 and passaged every 3-4 days when 
~80 % confluent. Passaging was done by removing media, rinsing with 0,085 M sodium 
citrate, adding 5mL 0.05 % trypsin EDTA (Invitrogen, cat#25300-054) and incubating 5 
minutes at 37 °C in 5 % CO2. 10mL DMEM was added and cells were separated to single 
cells by pipetting. About 1mL was transferred to a new T175 flask with 29 mL DMEM. 
3.2.2 Extraction of RNA 
RNA was extracted by using the spin column protocol supplied in the kit E.Z.N.A. Total RNA 
KIT I (Omega Bio-Tek, cat#R6834-02). RNA was eluted in 30µl DEPC H2O and the 
concentration was measured on a Nanodrop-1000 V3.7 (Thermo Scientific) 
spectrophotometer. 
3.2.3 cDNA synthesis 
For cDNA synthesis the RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas, 
#K1631) was used according to manufacturer’s protocol. Approximately 200ng RNA was 
used for a reaction of 20µl. The reaction was run on a 96-well Veriti Thermal Cycler 
(Applied biosystems, #603666).  
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3.2.4 Quantitative RT-PCR 
Primers were designed using the online tool Primer3 (Untergasser et al., 2012), and are listed 
in table 3. qPCR was performed by adding 5 µl iTaq Universal SYBR Green Supermix (BIO-
RAD #172-5121), 1 µl cDNA, primers in a final concentration of 0.5µM, and DEPC H2O to a 
total reaction volume of 10 µl. Samples were analyzed on a Stratagene MX3005P (Agilent 
Technologies) using FAM and ROX filters. Data was collected and analyzed and melting 
curves was determined using the MXPRO software V4.10. The thermal profile included a 5 
min activation period at 95°C, followed by 40 cycles of 15 sec denaturation at 95°C, 35sec 
annealing at 55 °C, and 35 sec elongation at 72 °C. Fluorescence was collected at the 
elongation step. The melting curve was used to determine level of primer-dimers and 
specificity of products. ROX was used as a reference dye. Data is collected as Ct values 
calculated by the software from the threshold set by the background and ROX signal. 
Table 3 – Primers used for quantitative RT-PCR amplification 
Primer name Primer sequence 
YAP1 qPCR F TAGCCCTGCGTAGCCAGTTA 
YAP1 qPCR R TCATGCTTAGTCCACTGTCTGT 
Sucrase isomaltase qPCR F TTTTGGCATCCAGATTCGAC 
Sucrase isomaltase qPCR R ATCCAGGCAGCCAAGAATC 
CDX2 qPCR F ACTACAGTCGCTACATCACCA 
CDX2 qPCR R GAAGACACCGGACTCAAGGG 
RPLP0 qPCR F GCAATGTTGCCAGTGTCTG 
RPLP0 qPCR R GCCTTGACCTTTTCAGCAA 
 
3.3 Transfection of Caco-2 and HEK293 cells 
3.3.1 Transfecting with PEI25 
Caco-2 or HEK293 cells were seeded in 24 well plates (Costar, 3526) at 50.000 cells/well. At 
80% confluence the media was changed and transfection reagent was prepared. PEI25 
(Polyethyleneimine (Alfa Aesar, #43896)) was diluted with 150mM NaCl to a final concentration 
of 2µM. For one well the transfection mix contained 50 ng plasmid, either pgl4.10 control or 
pGL4.10 plasmids containing YAP1 regulatory sequences, 25 ng CMV-LacZ plasmid for β-
galactosidase assay, and 25 ng of either pCMV-CDX2 from hamster, pCMV-HNF4α, or 
pCDNA3.1+ as an empty CMV vector. Finally 200 ng pBluescript SK+ was added to adjust the 
total DNA concentration pr. well to 300 ng. The transfection mix volume was adjusted with 150 
mM NaCl to 25 µl pr. well and mixed with an equal volume of 2 µM PEI25 (polyethylenimine, 
MW=25 kDa). The reaction was incubated 60 minutes at room temperature and applied to the 
cells by gently dropping 49 µl into each well. The plates were centrifuged at 1200 rpm for 3-5 
minutes and incubated for 4 hours at 37 °C and 5 % CO2 before the media was changed. The cells 
were then grown for 48 hours before assayed for β-galactosidase and luciferase activity. 
3.3.2 Measuring Luciferase and Beta-galactosidase activity 
For measuring both luciferase and beta-galactosidase activity the Dual Light assay kit 
(Invitrogen, #T1004) was used. Cells were harvested by removing media and washing with 
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PBS (2.7 mM KCl, 137 mM NaCl, 1.4 mM KH2PO4, and 4.3 mM Na2HPO47H2O) followed by 
adding 130 µl lysis solution, added DTT to a concentration of 0.5 mM. The plates were 
shaken lightly for 5 minutes and stored on ice.  
Luciferase activity was measured by adding 25 µl Buffer A to 10 µl cell lysate and loading it 
on a luminometer (Berthold, Lumat LB 9501) where 100 µl Buffer B, supplemented with 
galacton-plus 1:100 was injected. Activity was measured for 5 seconds. After 30 minutes β-
galactosidase activity was assayed by injecting the reactions with 100 µl Accellerator II and 
measuring for 5 seconds.  
 
3.4 Chromatin immunoprecipitation assay and analysis 
Two separate Immunoprecipitations from Caco-2 cells were used. Both sets were done 
following the protocol described in (Coskun et al., 2012). One set, including CDX2 and 
Hemagglutinin (HA) precipitation was kindly provided by Mehmet Coskun. The other set 
including CDX2, HNF4α, and HA precipitation was kindly provided by Jesper T. Troelsen. 
In short the Caco-2 cells were cross-linked by formaldehyde treatment 5 days after reaching 
confluence. After sonication a volume corresponding to 1 % of the input DNA was saved for 
control. Specific antibodies were applied and the precipitation occurred overnight. After 
recovering immunocomplexes with magnetic beads they were eluted and the protein-DNA 
crosslinks were reversed by incubation in 5 M NaCl overnight. RNA and Protein was 
degraded by RNase A and proteinase K, and the DNA was recovered using phenol-chloroform 
extraction and ethanol precipitation. 
Both precipitations were assayed with qPCR for CDX2 and HA binding to YAP1 promoter 
and DRE. One was further assayed for HNF4α binding. Primers were designed using the 
online tool primer3 (Untergasser et al., 2012) and is seen in table 4. qPCR was performed by 
adding 5 µl SsoFast EvaGreen Supermix with Low ROX (BIO-RAD, #172-5210), 1 µl ChIP 
DNA or H2O for control, primers in a final concentration of 0.5 µM, and H2O to a total 
reaction volume of 10 µl. Samples were loaded on a Stratagene MX3005P (agilent 
technologies) and Ct values measured. The amount of ChIP-DNA was calculated as a 
percentage of the input DNA (relative quantification) by the delta-delta method (Livak & 
Schmittgen, 2001). 
Table 4 – Primers used for ChIP analysis 
Primer name Primer sequence 
YAP1-Promoter F AGGCCAAGTCCTGCCTAGTT 
YAP1-Promoter R TTAAAAAGCAATGGCGATCC 
YAP1-DRE F CCTCTGGTCACAGTGTGGAA 
YAP1-DRE R TTGCCTGGACATACTCACCA 
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3.5 Electrophoretic mobility shift assay (EMSA) 
3.5.1 Designing and annealing of oligonucleotides 
Two type of oligonucleotides were designed, one type to mimic the TFBS at a length of 24 nt 
and another type to mutate the binding site and replace it with a restriction site. Mutational 
oligonucleotides were 34-48 nt and were designed with a 5’ overhang to enable radioactive 
labeling.  
The single stranded oligonucleotides were annealed by mixing 250 pmol of each and adding 
NaCl to a final concentration of 0.1 M and then placing them in a 95 °C heatblock which was 
passively cooled to room temperature.  
3.5.2 Labeling probes with γ-32P ATP 
2.5pmol annealed oligonucleotide was mixed with 5 units of T4 Polynucleotide Kinase 10 
U/µL (Thermo scientific, #EK0031), 1µl 10X forward kinase buffer A (500mM Tris-HCl pH 
7.6, 100mM MgCl2, 50 mM DTT, 1 mM spermidine), 5 µl [γ-32P]-ATP (3000Ci/mmol 5 
mCi/ml EasyTide Lead, 250 µCi, PerkinElmer #NEG502H250UC), and 2.5 µl H2O. 
The reaction was incubated at 37 °C for 30 minutes after which 20 µL 1X TE (pH 8.0, 10mM 
Tris-HCl containing 1mM EDTA•Na2) was added. The probes was then purified with Illustra 
MicroSpin G-25 Columns (GE Healthcare, #27-5325-01) and diluted with 1X TE to a total 
volume of 100 µL. 
3.5.3 Running the EMSA reaction 
The EMSA reaction included 1 μl differentiated Caco-2 nuclear extract, 4 μl dialysis buffer 
(25 mM Hepes pH 7.6, 0.1 mM EDTA, 40 nM KCl, and 10 % glycerol), 10 μl Gelshift buffer 
+ (25mM Tris-HCl pH 7.5, 5 mM MgCl2, 5 % Ficoll 400, 2.5% glycerol, 60 mM KCl, 0.5 mM 
EDTA, 1 mM DTT, and protease inhibitors), and 0.5 μl dI-dC (homopolymer of deoxyinosine 
and deoxycytidine). Furthermore the competition assay contained 1 μl of unlabeled oligos, 
either unspecific, wild type, or oligonucleotides with mutations introduced in the TF binding 
sites (CDX2, HNF4a, or HA). For the super shift assay 1 μl of antibody was added, either 
CDX2-antibody (BioGenex, cat#MU392A-UC) HA-probe Antibody (hemagglutinin from 
goat, Santa Cruz Biotechnology,Y-11 X ,#SC-805 X) or HNF4a Antibody (Rabbit, Santa Cruz 
Biotechonolgy, SC 171 X, # sc-8987 X ) was added. The reaction mix was incubated 20 
minutes on ice, and then added 1 μl of 32-P probe followed by 20 minutes incubation on ice. 
Before gel-loading 2 μl of Gelshift loading buffer (10 % glycerol, 0.2 % Bromphenol blue 
and 0.5X Tris-borate-EDTA buffer (2X TBE, 44.5 mM Tris-HCL pH 8.0, 1 mM EDTA, and 
44.5 mM boric acid)) was added to the reaction mixture. The reaction mixture was loaded on 
a non-denaturing 5% polyacrylamide gel (Acrylamide (30%, 29:1 acrylamide/Bis-
acrylamide), using 0.5X TBE as running buffer. Buffer and gel was precooled and the 
electrophoresis was run for approximately 45 minutes under cooling and at 100 mV and 25 
mA/gel. The gel was dried on a Slab gel Dryer SGD4050 (Savant) for two hours and exposed 
on a phosphor-image screen for 24 hours. The phosphor screens were scanned on a Storm 840 
scanner (Molecular Dynamics) and the image was analyzed using the Image-Quant Software 
version 5.2. 
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Table 5 – Oligonucleotides used for Electrophoretic Mobility Shift Assay (EMSA) 
DS Oligonucleotide 
name 
DS oligonucleotide sequence 5´ 3´ 
Unspecific competitor  5´AACGTAGCTGATCGAATCGGTTAC 
   3´TGCATCGACTAGCTTAGCCAATGA 
YAP1-CDXM1 5´AGATACTTTTGAACTCTGCAGGCACCATTTAAGTT 
  3´CTATGAAAACTTGAGACGTCCGTGGTAAATTCAAA 
YAP1-CDX-1 5´TTTTGAACTATTTATTGCACCATT 
 3´AAACTTGATAAATAACGTGGTAAA 
YAP1-CDXM2 5´TTAGCAAAGTTCAGCCTCGAGGCCTTAAAGATGAT 
  3´ATCGTTTCAAGTCGGAGCTCCGGAATTTCTACTAC 
YAP1-CDX-2 5´AAGTTCAGCTTTATTGCCTTAAAG 
  3´TCAAGTCGAAATAACGGAATTTCT 
YAP1-HNF-M 5´ACATGTTCATGTTAGTCTAGATCAGCTTTATTGCC 
  3´GTACAAGTACAATCAGATCTAGTCGAAATAACGGA 
YAP1-HNF 5´TTCATGTTAGCAAAGTTCAGCTTT 
  3´AGTACAATCGTTTCAAGTCGAAAT 
YAP1-H+C-M 5´AACATGTTCATGTTATCTAGAGTTCAGTCTAGAGCCTTAAAGATGATG 
3´TTGTACAAGTACAATAGATCTCAAGTCAGATCTCGGAATTTCTACTAC 
YAP1-H+C 5´TCATGTTAGCAAAGTTCAGCTTTATTGCCTTA 
  3´GTACAATCGTTTCAAGTCGAAATAACGGAATT 
CDX1/2: CDX2 binding sites 1 or 2; HNF: HNF4α binding site; H+C: HNF4α+CDX2 binding site 2. Names 
containing M: Core sequence of TF binding site mutated by inserting a restriction site. 
 
3.6 Statistics 
Values are represented by means and the P-values have been determined by two-tailed 
student’s t-tests and significance levels are shown as *: P< 0.05; **: P< 0.01; ***: P< 0.001 
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4 Results 
4.1 Identifying CDX2 and HNF4α binding sites in the YAP1 gene 
4.1.1 Analyzing Caco-2 ChIP-seq data for CDX2 and HNF4α binding sites 
The YAP1 gene (refseq: NM_006106) was searched for possible CDX2 and HNF4α binding 
sites in Caco-2 ChIP-seq data obtained from Verzi et al. and Boyd et al. (Data not shown) 
(Verzi et al., 2010) and (Boyd et al., 2010) by importing it as a custom track into the UCSC 
genome browser along with the march 2006 NCBI36/hg18 assembly of the human genome. 
Two enriched areas were chosen, one in the promoter and one in a downstream area. The 
YAP1 promoter is spanning a 972 bp region from (-838 to +134) relative to the transcription 
start site (TSS) of YAP1. The other sequence is a downstream sequence, hereafter referred to 
as downstream regulatory element (DRE) and is spanning a 600 bp region (+73030 to 
+73630), figure 11. 
 
Figure 11 – Overview of the 122,818bp long YAP1 gene (NM_006106) as seen in the UCSC Genome Browser using 
NCBI36/hg18 genome assembly. The yellow and red boxes represent the location of the promoter and downstream 
regulatory element (DRE). The promoter and DRE positions on the figure are relative to the marked YAP1 
transcription start site (TSS) in pos +1. Each black bar represents a sequenced piece of DNA which has been 
identified in ChIP of CDX2 in Caco-2 cells by Verzi et al. The ChIP-seq peaks that have been circled by green are 
the two areas where CDX2 binding is most likely (Verzi et al., 2010) 
Because the YAP1 gene is relatively large, a more detailed view is provided for the promoter, 
figure 12 and the DRE, figure 13. 
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Figure 12 – Overview of the YAP1 promoter region as seen in the UCSC Genome Browser using NCBI36/hg18 
genome assembly. The yellow and red boxes numbered “1”, “2”, and “3” represent the location of CDX2 binding 
sites found by in silico analysis with the MATCH tool incorporated in the Transfac database (Kel et al., 2003), 
figure 15 and verified by EMSA, figure 17. The blue and red box numbered “4” marks a HNF4α site. Positions for 
binding sites (1:-775; 2:-750; 3:-85; 4:-20) are relative to the YAP1 transcription start site (TSS) circled in red. 
Five tracks have been imported into the browser. Track 1 is a custom track containing ChIP-seq data from (Verzi 
et al., 2010), where each black bar represents a sequenced piece of DNA which has been identified in ChIP of 
CDX2 in Caco-2 cells. Track 2 is similar to track 1, but contains HNF4α data. Track 3 is a list of TF binding sites 
discovered in the ENCODE project (Rosenbloom et al., 2013) by ChIP-seq analysis in different tissues, the signal 
strength is highest in darkest bars. TF’s marked with L have been found in liver tissue. Track 4 and 5 is DNaseI 
peaks and histone acetylation (H3K27Ac) respectively, both from the ENCODE project (Rosenbloom et al., 2013). 
 
In the YAP1 promoter a region with a substantial signal for both CDX2 and HNF4α in ChIP-
seq was identified in data obtained from Verzi et al. and Boyd et al. (Data not shown) figure 
12 track 1 and 2 (Boyd et al., 2010; Verzi et al., 2010). This indicates that both TF’s might 
bind to the promoter. The transcription factor ChIP-seq data from the Encyclopedia of DNA 
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Elements (ENCODE) project also contains a HNF4α signal as well as several signals from the 
known CDX2 co-factor EP300 and the EP300 co-regulator upstream transcription factor 1  
(USF-1), figure 12 track 3. Binding of TFs that is known to interact with CDX2 and/or 
HNF4α indicates accessible DNA binding sites on the gene in that area. The DNaseI peaks 
and histone acetylation data from the ENCODE project point to an open chromatin structure, 
suggesting that the YAP1 promoter is active in Caco-2 cells, track 4 and 5. 
The DRE region of YAP1 also contains a significant ChIP-seq signal for both CDX2 and 
HNF4α, figure 13 track 1 and 2. Interestingly the TF ChIP-seq data by the ENCODE project 
reveals several hepatic TF’s in addition to HNF4α. As in the promoter there is a significant 
signal from the CDX2 co-factor EP300 together with USF-1 and the activating protein 1 (AP-
1) components jun D proto-oncogene (JUND) and FOS-like antigen 2 (FOSL2), track 3. The 
ChIP-seq signal was found in hepatic cells, which like intestinal cells are derived from 
endoderm. These TF’s might therefore be part of a regulatory network directly and indirectly 
regulating YAP1 expression in Caco-2 cells. The DNaseI peak and high level of histone 
acetylation both indicate an open chromatin structure implying that the YAP1 DRE region is 
an active regulatory region, track 4 and 5.  
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Figure 13 - Overview of the YAP1 downstream regulatory element (DRE) region as seen in the UCSC Genome 
Browser using NCBI36/hg18 genome assembly. The yellow and red boxes numbered 1 and 3 represent the location 
of CDX2 binding sites found by in silico analysis with the MATCH tool (Kel et al., 2003) used on the Transfac 
database, Figure 15 and verified by EMSA, Figure 17. The blue and red box numbered “2” marks a HNF4α site. 
Positions for binding sites (1:+73180; 2:+73420; 3:+73430) are relative to the YAP1 transcription start site (TSS). 
Five tracks have been imported into the browser. Track 1 is a custom track containing ChIP-seq data from (Verzi 
et al., 2010), where each black bar represents a sequenced piece of DNA which has been identified in ChIP of 
CDX2 in Caco-2 cells. Track 2 is similar to track 1, but contains HNF4α data. Track 3 is a list of TF binding sites 
discovered by the ENCODE project (Rosenbloom et al., 2013) by ChIP-seq analysis in liver tissue and the signal 
strength is highest in darkest bars. Track 4 and 5 is DNaseI peaks and histone acetylation (H3K27Ac) respectively 
from the ENCODE project (Rosenbloom et al., 2013). 
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The in silico analysis revealed two areas of the YAP1 gene, one in the promoter region and 
one downstream in the so called DRE, both with a high probability of having CDX2 and 
HNF4α binding sites. 
4.1.2 Quantitative RT-PCR confirms binding of CDX2 and HNF4α to YAP1 
qPCR was performed on Caco-2 purified ChIP DNA to confirm CDX2 and HNF4a binding to 
the promoter and DRE regions of YAP1. Primers were designed to amplify the most enriched 
areas of the sequences. A high percentage of immunoprecipitated DNA compared to total 
input DNA translates to a strong protein-DNA binding because more of the cells will contain 
the bound protein. The HA protein does not bind to DNA and is used as a negative control 
measuring background. 
The YAP1 promoter CDX2 ChIP DNA level is about 0.1 % of the input DNA which is a 50-
fold increase from background, suggesting that CDX2 does bind to the promoter in vivo, 
figure 14. In the DRE it is about 0.2 % which is an increase of more than 100-fold, suggesting 
that CDX2 is bound twice as often to the DRE compared to the promoter region. 
The ChIP-seq signals implied that HNF4α would be bound to both the promoter and DRE 
region more often than CDX2 (figure 12 and figure 13), however the qPCR only showed a 4-
fold increase from background (0.008 %) in the promoter and a 17-fold increase in the DRE 
ChIP DNA (0.035 %) from the HNF4α precipitation compared to the control. Both of these 
are much lower than the CDX2 levels. Thus it is uncertain whether HNF4α binds to the YAP1 
promoter at all or if the binding is weak. The 17-fold HNF4α enrichment in the DRE suggests 
that the binding site is used In vivo but that the CDX2 signal is almost 9-fold stronger.  
 
Figure 14 – Quantification of Caco-2 DNA immunoprecipitated with either CDX2 or HNF4α antibodies. The 
amount of Caco-2 purified ChIP DNA was compared to the amount of input DNA. CDX2 enrichment compared to 
the HA control is evident in both the promoter and DRE, with 50-fold and 100-fold respectively. HNF4a 
enrichment was also found in both regions, although only a 4-fold higher signal was found in the promoter while a 
17-fold was observed in the DRE. Quantification was performed by RT-qPCR, n=2 and values are means. 
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The in silico identification of CDX2 and HNF4α sites in YAP1 together with the qPCR results 
revealed that CDX2 most likely binds to the YAP1 promoter and DRE sequences. Since a very 
low signal for HNF4α was detected in the promoter, it might only binds to the DRE. 
 
4.1.3 Transcription factor binding site analysis identifies binding sites in YAP1 
An in silico analysis was performed on both the YAP1 promoter and DRE sequences by 
utilizing the MATCH algorithm (Kel et al., 2003) in the Transfac® database to map the 
specific locations of the TF binding sites. Using a recognition matrix for CDX2 and HNF4α 
binding sites, three potential CDX2 sites and an HNF4α site were found in the promoter while 
two CDX2 sites and an HNF4a site were found in the DRE, figure 15.  
MATCH scores each possible binding site by assigning two scores, one for the core of the 
known binding sequence and an overall score for the entire binding sequence. A perfect 
match results in a score of 1, while non-perfect matches is awarded a score between 0 and 1. 
The core sequence is the most important factor for a functional binding site, and sequences 
with a non-perfect core match are much less likely to be in vivo sites. The overall score is an 
indicator of how similar the entire TFBS sequence is to a perfect match. A functional TFBS 
does not necessarily require a perfect match in overall score, but a higher score might 
indicate a site with stronger affinity.  
In the YAP1 promoter all three CDX2 sequences have a perfect core sequence score and a 
moderate overall score making them probable binding sites, figure 15 A. Taking the qPCR 
data from Caco-2 ChIP DNA, figure 14, into consideration one or several of the CDX2 sites 
are most likely biologically active in Caco-2 cells. The HNF4α site core sequence is not a 
perfect match but the somewhat high overall score makes it a probable binding site. Although 
considering the very weak signal from the qPCR analysis of ChIP DNA, it is not as likely that 
this site is functional. 
In the DRE the first CDX2 site has a perfect core sequence score and a high overall score 
suggesting that the site is functional, figure 15 B. This also applied to the second CDX2 site. 
The HNF4α site is even more likely to be active, with an almost perfect overall score. The 
analysis revealed that the predicted second CDX2 site and the HNF4α site shares four 
nucleotides in the non-core part of the sequences. Although the overlapping nucleotides are 
not part of the core sequences, this might indicate a functional competition or redundancy 
between the two transcription factors.  
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Figure 15 – In silico analysis of the YAP1 promoter (A) and DRE (B) using Transfac MATCH algorithm (Kel et al., 
2003) to identify possible binding sites for the transcription factors CDX2 and HNF4α. CDX2 sites are marked in 
yellow, HNF4α in red, and overlapping bindingsite nucleotides in pink. The MATCH score, consisting of a core 
sequence match followed by an overall score was determined for each site. Scores are ranked from 0 to 1, where 1 
is a perfect match to the known binding sequence of the TF.  
4.1.4 EMSA reveals in vitro binding of CDX2 and HNF4α to the YAP1 DRE 
After the in silico analysis with Transfac the focus was on confirming the two CDX2 and one 
HNF4α sites predicted in the DRE sequence. An electrophoretic mobility shift assay was used 
to reveal in vitro binding between oligonucleotides containing the TFBS sequences and 
CDX2 or HNF4α. Mutations were introduced by constructing oligonucleotides where the core 
sequence of the binding sites was replaced by restriction sites, figure 16.  
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Figure 16 – Overview of the mutations in CDX2 and HNF4α binding sites in the YAP1 DRE. Mutations were 
introduced by replacing core sequences with restriction sites. The specific oligos are listed in Table 5. 
The EMSA is performed to ascertain whether the endogenous CDX2 and HNF4α in Caco-2 
cells is able to bind to the three chosen putative binding sites and to determine if the binding 
is specific. Each band on the gel represents the radiolabelled oligonucleotide, either unbound 
or bound in a complex with proteins in the Caco-2 nuclear extract. The intensity of the bands 
is determined by the amount of radiolabeled oligonucleotide they contain. 
 
CDX2 binding site 1 
In figure 17 A lane 1 three bands containing the oligonucleotide with the first CDX2 site of 
the DRE are detected. The lower bands are consistently present in all lanes on all EMSAs and 
contains the surplus of the unbound radiolabeled oligonucleotide and will not be regarded as 
a ‘band’ hereafter. The two remaining bands contain the oligonucleotide with the first CDX2 
binding site in complex with proteins. The difference in intensity indicates a difference in 
binding strength of the complexes. In lane 2 the bands remain after adding an unspecific oligo 
while they disappear when adding unlabeled CDX2-1 oligo (lane 3), demonstrating 
specificity between the CDX2-1 oligo and the bound proteins. In lane 4 the CDX2-1 oligo 
with mutated core binding sequence does not compete for binding to either complex, 
demonstrating that the core sequence is essential for binding both proteins. In lane 5 only the 
high intensity band supershifts with addition of the CDX2 antibody while the non-specific 
antibody HA (lane 6) has no effect on any of the bands. This establishes CDX2 as the protein 
in the high intensity band whereas the protein in the low intensity band remains unknown. 
 
CDX2 binding site 2 in the YAP1 DRE 
Running the EMSA with the oligonucleotide containing the second CDX2 binding site only 
yielded one band but was otherwise similar to the EMSA of the first site, figure 17 B. This 
confirms that CDX2 also binds to the second CDX2 site in the YAP1 DRE. A moderate 
amount of unspecific binding or smear was present below the visible band, possibly 
originating from an unstable oligonucleotide-protein complex dissociating as it moves 
through the gel. It could also be a result of the radiolabeled oligo binding to unspecific DNA-
binding proteins not sequestered by the poly(dI-dC). 
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Figure 17 – Electrophoretic mobility shift assay (EMSA) on the CDX2-1 site (A) and the CDX2-2 site (B) in the 
YAP1 DRE. Full size figures can be found in appendix I. All wells contain: 1 μL differentiated Caco-2 nuclear 
extract, Buffers, 0.5 μg unspecific competitor poly(dI-dC), and 2.5 fmol radioactive labeled probe. In addition the 
wells contain: 1) Empty, 2) Unspecific control probe, 3) non-labeled probe – competitor, 4) Mutated non-labeled 
probe, 5) Specific antibody (CDX2), 6) Unspecific antibody (HA).  
A: Lane 1: One high intensity band and one low intensity band is visible. Lane 2: No competition, the same two 
bands are visible. Lane 3: Both bands were competed by the unlabeled oligo. Lane 4: No competition, same two 
bands are visible. Lane 5: The high intensity band supershifted and the low intensity band is unchanged. Lane 6: 
No supershift observed, same two bands observed. 
B: A low amount of smear (unspecific binding) is visible throughout the EMSA. Lane 1: One very high intensity 
band is visible. Lane 2: The band is removed by competition. Lane 3: The band was completely outcompeted by the 
unlabeled oligo. Lane 4: A very weak competition, the band is still high intensity. Lane 5: The band supershifted. 
Lane 6: No supershift observed. 
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HNF4α binding site in the YAP1 DRE 
In figure 18 lane 1 one high intensity band is visible. The band is not affected by adding the 
unspecific oligo (lane 2) but was competed by the unlabeled HNF4α oligonucleotide. The 
oligonucleotide is therefore specific for the bound protein. Interestingly using the oligo with 
a mutated core HNF4α binding sequence exerted a weak competition with the labeled oligo 
(lane 4) showing that the protein is still able to maintain a weak interaction with the oligo 
without the original core sequence intact. The HNF4α antibody created a supershift of the 
band (lane 5) while the unspecific antibody did not (lane 6). This demonstrates that the 
protein binding to the oligo is HNF4α. 
 
 
Figure 18 - Electrophoretic mobility shift assay (EMSA) on the HNF4a site in the YAP1 DRE. Full size figure can 
be found in appendix I. All wells contain: 1 μL differentiated Caco-2 nuclear extract, Buffers, 0.5 μg unspecific 
competitor poly(dI-dC), and 2.5 fmol radioactive labeled probe. In addition the wells contain: 1) Empty, 2) 
Unspecific control probe, 3) non-labeled probe – competitor, 4) Mutated non-labeled probe, 5) Specific antibody 
(HNF4α), 6) Unspecific antibody (HA).  
A low amount of smear (unspecific binding) is visible throughout the EMSA.  
Lane 1: One high intensity band is visible along with one low intensity band barely noticeable just below. Lane 2: 
No competition, the same two bands are visible. Lane 3: Both bands were outcompeted by the unlabeled oligo. 
Lane 4: Some competition but there is still a medium intensity band. It is difficult to distinguish if both bands are 
affected. Lane 5: Both bands have supershifted. Lane 6: No supershifts, the same two bands were observed. 
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CDX2 binding site 2 and HNF4α binding site in the YAP1 DRE 
Lane 1 in the EMSA containing the oligonucleotide with both the second CDX2 site and the 
HNF4α site contained 2 bands, figure 19. The protein-oligo interactions are specific because 
none of them were affected by adding unspecific oligo (lane 2) but both were competed by 
the unlabeled oligo (lane 3). In lane 4 the oligo with both core binding site sequences mutated 
only weakly competed for the proteins leaving both bands visible. This indicates that a minor 
amount of the mutated oligo could bind either CDX2 or HNF4α or both. When adding CDX2 
antibody the lower band but not the higher band shifts upwards (lane 5) and the opposite is 
true when adding HNF4α antibody (lane 6). None of the bands are affected by the unspecific 
antibody (HA) lane 7. This demonstrates that the oligonucleotide binds to both CDX2 and 
HNF4α, but not at the same time, as this would result in a third band. 
 
Figure 19 - Electrophoretic mobility shift assay (EMSA) on both the overlapping CDX2-2 site and HNF4a site in 
the YAP1 DRE. Full size figure can be found in appendix I. All wells contain: 1 μL differentiated Caco-2 nuclear 
extract, Buffers, 0.5 μg unspecific competitor poly(dI-dC), and 2.5 fmol radioactive labeled probe. In addition the 
wells contain: 1) Empty, 2) Unspecific control probe, 3) non-labeled probe – competitor, 4) Mutated non-labeled 
probe, 5) Specific antibody (CDX2), 6) Specific antibody (HNF4α), 7) Unspecific antibody (HA).  
A low-to-moderate amount of smear (unspecific binding) is visible throughout the EMSA.  
Lane 1: Two very close bands are observed, the lower one more intense than the upper one. Lane 2: No 
competition, the same two bands are visible. Lane 3: Both bands were outcompeted by the unlabeled oligo. Lane 4: 
Weak competition by the mutated oligo but both bands are still visible. Lane 5: The lower and more intensive band 
has supershifted, the other band is unchanged. Lane 6: The low intensity band has supershifted with HNF4α 
antibody while the high intensity band is unchanged. Lane 7: No supershifts, the same two bands were observed. 
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4.2 Functional characterization of CDX2 and HNF4α interaction with YAP1 
4.2.1 Luciferase assay demonstrates regulatory activity of the YAP1 DRE 
After identifying several CDX2 and HNF4α binding sites the next step was to investigate 
their functional effects on gene transcription in Caco-2 cells. The first step was testing 
whether any changes could be observed in transcription levels of reporter plasmids containing 
the promoter sequence from YAP1, with and without the DRE inserted. This can show 
whether the promoter is active in Caco-2 cells and whether the DRE regulates the level of 
transcription. 
 
Figure 20 – Caco-2 cells are transfected with luciferase reporter constructs containing the YAP1 promoter and the 
promoter+DRE (Downstream regulatory element) to assay transcriptional activity. Luciferase activity is stated in 
mean values relative to the YAP1 promoter construct and corrected by beta-galactosidase activity. Error bars are 
SD values, and *** equals p<0.0001, n=4. 
As seen on figure 20 the YAP1 promoter construct is transcriptionally active on its own in 
Caco-2 cells with luciferase activity about 10-fold higher than background. More 
interestingly, a considerable and significant increase in luciferase and thus transcriptional 
activity of about 12 fold is seen when adding the DRE to the promoter construct. The DRE 
seems to function as a potent enhancer of transcription in Caco-2 cells. 
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4.2.2 Overexpressing CDX2 and HNF4α affects transcription levels of YAP1 reporter 
plasmids in Caco-2 cells but not HEK293. 
The YAP1 promoter and DRE are transcriptionally active in Caco-2 cells. To further elaborate 
on the role that CDX2 and HNF4α might have in this transcriptional regulation an 
overexpression was performed in Caco-2 cells. YAP1 reporter constructs were co-transfected 
with either CDX2 or HNF4α expression plasmids. 
 
Figure 21 - Caco-2 cells are transfected with luciferase reporter constructs containing the YAP1 promoter and the 
promoter+DRE (Downstream regulatory element) to assay transcriptional activity. For overexpression of CDX2 
and HNF4α, expression plasmids are co-transfected into the cells. Luciferase activity is stated in mean values 
relative to the YAP1 promoter construct and corrected by beta-galactosidase activity. Error bars are SD values, ** 
equals p<0.001, *** equals p<0.0001, n=4. 
 
Overall the overexpression assay shows a clear effect of CDX2 and HNF4α on the 
transcriptional activity of the YAP1 promoter in Caco-2 cells, figure 21. Overexpression of 
CDX2 more than doubles the activity of the YAP1 promoter, while HNF4α seems to have no 
or little effect. This corresponds well with the findings of the qPCR performed on the ChIP-
DNA from Caco-2 cells, figure 14. It indicates that CDX2 binds to the YAP1 promoter and 
regulates its transcription. It further suggests that HNF4α might not regulate the YAP1 
promoter, or at least that an overexpressed level of HNF4α exerts the same regulation as the 
endogenous amount. 
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When combining the promoter with the DRE, the endogenous level of TF’s present in Caco-2 
cells increases the expression almost 12 fold compared to the promoter alone. Overexpressing 
HNF4α increases expression levels almost 3 fold compared to endogenous levels. The DRE 
seems to be an even more potent enhancer when combined with HNF4α, which suggests that 
the enhancing effect is exerted by HNF4α binding to the DRE. Interestingly overexpression 
of CDX2 either directly or indirectly inhibits the enhancer effect of the DRE by about 50 % 
compared to endogenous TF levels. This silencing effect can possibly be explained by CDX2 
competing for binding to the HNF4α binding site in the DRE which overlaps the second 
CDX2 binding site. 
The YAP1 regulation by CDX2 and HNF4α was first as shown analysed in Caco-2 cells, 
which are intestinal cells with an endogenous expression of both TF’s and their necessary 
cofactors. A similar overexpression experiment was performed in HEK293 cells to reveal 
more about the way the TF’s regulate the YAP1 expression, figure 22. 
 
Figure 22 – HEK293 cells are transfected with luciferase reporter constructs containing the YAP1 promoter and 
the promoter+DRE (Downstream regulatory element) to assay transcriptional activity. For overexpression of 
CDX2 and HNF4α, expression plasmids are co-transfected into the cells. Luciferase activity is stated in mean 
values relative to the YAP1 promoter construct and corrected by beta-galactosidase activity. Error bars are SD 
values, n=4. 
In HEK293 cells the expression level of the YAP1 promoter construct is low similar to 
expression in Caco-2 cells. In contrast to the Caco-2 cells, overexpressing CDX2 does not 
affect transcription and neither does overexpression of HNF4α, figure 22. Adding the DRE 
both with and without overexpression of both TF’s does not affect the activity either. This 
demonstrates that CDX2 and HNF4α regulation of YAP1 is dependent on other factors present 
in Caco-2 cells but not in HEK293 cells. Thus we might have found parts of a transcriptional 
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system including CDX2 and HNF4α, which is regulating the YAP1 gene transcription 
specifically in Caco-2 cells or perhaps intestinal cells.  
 
4.2.3 The first CDX2 site in the DRE is important for transcriptional activity 
The transfections of the YAP1 reporter plasmids and overexpression experiments 
demonstrated that CDX2 and HNF4α have a substantial effect on the transcriptional activity 
of YAP1 in Caco-2 cells. Additionally it seems like their main effect can be attributed to their 
direct or indirect effect on the DRE, given the right cofactors. To investigate if their 
regulation is exerted by directly interacting with any of the three specific binding sites, Caco-
2 cells was transfected with YAP1 reporter plasmids where the DRE contained mutated CDX2 
and HNF4α binding sites, for an overview of sites see figure 16. 
 
Figure 23 – Caco-2 cells are transfected with luciferase reporter constructs containing the YAP1 promoter and the 
promoter+DRE (Downstream regulatory element) to assay transcriptional activity. The core sequences of CDX2 
and HNF4α binding sites, including the overlapping CDX2 site 2 and HNF4α is mutated and plasmids are 
transfected into Caco-2 cells. The double mutant has both core sequences replaced. Luciferase activity is stated in 
mean values relative to the YAP1 promoter construct and corrected by beta-galactosidase activity. Error bars are 
SD values, ** equals p<0.001, *** equals p<0.0001, n=8. 
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The transcriptional activity of the YAP1 promoter+DRE reporter constructs with mutated TF 
binding sites are all lower than the intact construct, figure 23. Most noteworthy is the 
dramatic decrease in activity of the construct with the first CDX2 core binding site mutated. 
The almost 6-fold decrease from the original DRE construct tells us that the first CDX2 site 
is important for the enhancer effect of the DRE accounting for more than any of the other 
mutations. It is unexpected that removing the binding site of CDX2 should result in a 
decrease in activity when overexpression of CDX2 also caused a decrease, figure 21. Perhaps 
the binding site is necessary for recruiting the transcriptional machinery while an overload of 
CDX2 causes an imbalance elsewhere ultimately leading to a silencing effect of the YAP1 
enhancer. 
Mutating the core of the second CDX2 site moderately decreases activity with about 1.4-fold. 
Similarly, mutating the core of the HNF4α site also results in a moderate decrease of about 
1.6-fold from the original construct. The mutation of both the second CDX2 site and the 
partly overlapping HNF4α site results in a decrease of about 2-fold more than the decrease of 
any of the two mutations separately, but not as large as both of them put together. These 
results demonstrate that the transcriptional activity is not simply a sum of the contribution of 
single TF’s binding to single binding sites. Additionally the data suggests that the sequence 
of the first CDX2 binding site is important for the enhancer effect of YAP1 DRE in Caco-2 
cells. 
 
4.2.4 CDX2 sh-RNAi knockdown in Caco-2 cells affects CDX2 target gene, but not 
CDX2 RNA level. 
From the TF overexpression assay and the analysis of mutated binding sites in the YAP1 DRE 
it was demonstrated that both the YAP1 promoter and the DRE contain binding sites for 
CDX2 that are important for YAP1 transcriptional regulation. The role of CDX2 in the 
regulation is unclear due to the apparent conflicting results from the knockdown and 
overexpression assays. Mutating the first CDX2 binding site decreases transcription levels, 
but overexpression also seems to decrease transcriptional activity. To further elaborate on the 
role of CDX2’s regulation of YAP1 it was attempted to knock down CDX2 RNA and in turn 
protein levels by RNAi using a lentiviral induction of sh-RNAi targeting CDX2 mRNA in 
Caco-2 cells, figure 24. 
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Figure 24 – Short-Hairpin Knockdown of CDX2 in Caco-2 Cells. sh-RNA is introduced by induction with a 
lentiviral vector. The CDX2-sh-RNA target sequence is: CAAATATCGAGTGGTGTACAC, as a control a 
scrambled sh-RNA with no known targets is also induced, sequence: CTAAGGTTAAGTCGCCCTCG. mRNA levels 
of CDX2, YAP1 and SI (Sucrase Isomaltase) are determined by RT-qPCR one week after sh-RNAi induction. SI is 
used as a reference gene as its expression is tightly regulated by CDX2. mRNA values for CDX2-sh are relative to 
values of the scramble-sh for each gene. Error bars are SD values, and *** equals P<0.001, n= 4. 
Sh-RNAi knockdown yielded some inconsistent results. The first two bars show the CDX2 
mRNA level of the cells induced with the either sh-RNA targeting CDX2 or a scrambled sh-
RNA with no known targets as a control. Surprisingly it was not possible to detect a 
significant decrease in the CDX2 mRNA as expected. It is even more surprising that the 
CDX2 reference gene SI (Sucrase Isomaltase), which is normally directly regulated by 
CDX2, was significantly decreased by more than 80 % compared to the scrambled RNAi. It 
was expected that the CDX2 sh-RNA which is perfectly complementary to a piece of the 
CDX2 sequence would result in a degradation of the CDX2 mRNA. It is possible that the 
CDX2 sh-RNA instead inhibits translation of the mRNA, resulting in a decrease of CDX2 
protein but not mRNA. This can explain why SI is knocked down while CDX2 mRNA levels 
remain relatively constant. 
The YAP1 mRNA seems slightly up-regulated by about 16 percent, but the result is not 
statistical significant. Because of the unexpected unchanged CDX2 mRNA level it is not 
possible to attribute the slightly higher YAP1 mRNA levels as a direct outcome of CDX2 
regulation. A more clear understanding of these results could be obtained by measuring 
protein levels in the cells instead of mRNA levels. 
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5 Discussion 
5.1 CDX2 and HNF4α bind to YAP1 
The initial analysis of ChIP-seq DNA immunoprecipitated with CDX2 or HNF4α antibodies 
revealed several possible binding sites in the YAP1 gene. The data suggests that both CDX2 
and HNF4α had been bound to the YAP1 promoter and DRE at the time of crosslinking. This 
data is by itself a good indication of an in vivo protein-DNA interaction. To gather more 
evidence for this hypothesis the DNA structure was assessed for its suitability for protein 
binding. Data tracks from the ENCODE project was compared with the ChIP-seq data. The 
ENCODE data revealed both DNaseI peaks and surrounding Histone 3 lysine 27 acetylation 
(H3K27Ac) enrichment in the promoter area where TF binding was indicated. DNaseI peaks 
and H3K27Ac are generally good indicators of an open and accessible chromatin structure. 
This is because DNaseI digests open DNA faster than a closed chromatin structure and that 
H3K27 acetylation enhances transcription of nearby DNA. Further support was found in the 
ENCODE TF ChIP-seq data track, which also included possible binding sites for HNF4α 
along with the CDX2 and HNF4α partners and/or regulators EP300, FOSL2, USF-1, and 
JUND. Combined, all the analyzed data indicates that CDX2 and HNF4α is likely to bind 
somewhere in the suggested area of the YAP1 promoter. It should be noted though, that both 
the signals from the ChIP-seq data on track 1 and 2 and the ENCODE track 3 indicated a 
weak-to-moderate signal in the promoter, figure 12. These signals are comparatively stronger 
in the DRE region, indicated by the larger peaks on track 1 and 2, and darker color on track 3, 
figure 13. Similarly to the promoter region, the DRE region contains a DNaseI peak and 
H3K27Ac enrichment, representative of a transcriptionally active region. 
This analysis of ChIP-seq data should ideealy show CDX2 and HNF4α binding to the YAP1 
gene in vivo. Not every sequenced piece of ChIP-DNA is a specific in vivo binding site for 
the TF’s. The relatively low signals in the YAP1 promoter could perhaps be partly due to 
binding of protein complexes containing the immuniprecipitated protein. If for example 
HNF4α forms a complex with a different TF and that TF then binds the DNA, then a 
subsequent HNF4α antibody purification would still yield the complex-bound DNA. The 
transcriptionally active region of the YAP1 promoter contains several binding sites for TF’s 
that might interact with HNF4α and CDX2. A study by Mink et al. demonstrated that the 
transcriptionfactor EP300 can form a complex with CCAAT/enhancer binding protein beta 
(CEBP) which is a member of the CREB binding proteins, and v-myb avian myeloblastosis 
viral oncogene homolog (Myb) (Mink, Haenig, & Klempnauer, 1997). Another study found 
that HNF4α interacts with the family of CREB binding proteins (CREBBP) (Yoshida et al., 
1997). Both EP300 and CEBP signals was found in the YAP1 promoter of the ENCODE ChIP-
seq data. It is thus possible that an HNF4α-CEBP-EP300 complex or other HNF4α complexes 
could be the reason of some of the signal strength in the ChIP-seq analysis. Though it cannot 
be rules out that HNF4α still might affect YAP1 expression levels through this binding of 
secondary TF’s.   
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A quantitative PCR was performed on ChIP-DNA isolated from Caco-2 cells to verify and 
quantify the results found by analyzing ChIP-seq data, figure 14. This experiment measured 
the difference in CDX2 and HNF4α precipitated DNA from the YAP1 promoter and DRE 
compared to the background level using a HA antibody. The hypothesis was that there would 
be a significant increase of DNA from the possible binding sites of CDX2 and HNF4α. The 
quantification is a measure of the difference between the amounts of DNA obtained from 
each immunoprecipitation. A higher amount of DNA in precipitated samples indicates that 
more of the cells had the specific protein bound to its DNA at the time of crosslinking. 
A 50-fold higher amount of CDX2 immunoprecipitated DNA than of background DNA was 
detected at the predicted binding site in the YAP1 promoter, indicating CDX2 binding to the 
promoter. However, the amount of DNA from HNF4α immunoprecipitated cells was almost at 
background level. This result conflicts with the initial hypothesis, and suggests that HNF4α 
does not bind to this part of the YAP1 promoter. It is unclear why the ChIP-seq data and 
ChIP-qPCR data does not both show a signal. Because the binding of HNF4α is dependent on 
the specific differentiation status of the cell, it is possible that differences between the time 
of cell harvest and the growth patterns might influence HNF4α binding differently in each 
assay. To test whether HNF4α binding can be affected by these differences it would be 
possible to set up an experiment harvesting the Caco-2 cells at different time intervals and 
assaying ChIP-DNA amount. 
A 100-fold increase in CDX2 ChIP-DNA and a 17-fold increase in HNF4α ChIP-DNA over 
background were detected in the YAP1 DRE. This is evidence for the hypothesis of CDX2 and 
HNF4α binding to the DRE. The amount of DNA suggests that CDX2 binds twice as often as 
it does in the promoter area. Because the result from the promoter precipitation was 
contradicting the ChIP-seq result it is difficult to conclude much from its quantitative level. 
Even though the level of HNF4α ChIP-DNA is significantly higher than the background, it is 
much lower than the CDX2 level. This relationship is reversed when looking at the signal 
strength of the ChIP-seq data, figure 13. 
Together the in silico analysis and the RT-qPCR strongly suggest that CDX2 and HNF4α bind 
to the YAP1 DRE sequence and that CDX2 binds to the YAP1 promoter sequence. 
Additionally, HNF4α might bind to the promoter sequence of YAP1 but this then probably 
depends on temporal factors or other unknown factors. The discovery of these regulatory sites 
might be important for understanding how YAP1 is regulated in the intestines. 
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5.2 Identification of specific CDX2 and HNF4α binding sites 
5.2.1 Transfac analysis 
The Transfac analysis was used to predict specific locations for TFBS’s in YAP1, figure 15. 
Based on the ChIP-DNA experiments the expectation was that it would be possible to detect 
at least one binding site for CDX2 in the promoter and DRE, as well as an HNF4α site in the 
DRE and possible also in the promoter. The Transfac analysis predicted three likely CDX2 
sites and a somewhat likely HNF4α site in the promoter sequence. The core sequence of the 
HNF4α site was not a perfect match and is thus considered either a weak site or a falsely 
predicted site. From the current evidence it seems unlikey but not impossible that HNF4α 
binds to the YAP1 promoter. There is an indication that a weak functional site might exist, but 
whether it is only active at certain time or under certain circumstances is unknown.  
In the DRE sequence, two CDX2 sites and an HNF4α site was predicted with a high 
probability.  The predicted HNF4α site has an almost perfect overall score, indicating a very 
likely and possibly high affinity binding site. 
 
5.2.2 EMSA experiments 
To test the Transfac predictions in vitro an EMSA experiment was set up, but due to practical 
limitations the EMSA analysis was limited to the YAP1 DRE sequence and the three predicted 
binding sites. It was believed that the EMSA would show specific binding of both CDX2 and 
HNF4α because of the strong signals in the ChIP-seq analysis and because of the high 
probability prediction of binding sites. 
The two EMSA’s with the CDX2 site oligos CDX2-1 and CDX2-2 confirmed in vitro binding 
of CDX2 to the predicted binding sites, figure 17. However, an unknown protein was also 
found to specifically bind the CDX2-1 sequence. This interaction was weak compared to the 
CDX2 protein interaction, but is interesting because it could possibly have an effect on the 
binding affinity of CDX2 and possibly on regulation of the YAP1 gene. It would therefore be 
interesting to identify this protein. According to the EMSA, the unknown protein is probably 
larger in its native form than CDX2, as it migrates slower in the gel. The CDX2-1 sequence is 
from an area with several TFBS’s and the protein might be among one of the TF’s found in 
the ENCODE data, figure 13. Both JUND and FOSL2 are potential candidates, because they 
are larger than CDX2 and they are believed to affect CDX2 regulation. 
 
The EMSA with the HNF4α predicted binding site oligo revealed a specific binding of 
HNF4α to the YAP1 DRE as expected, figure 18. In this assay the HNF4α oligo with mutated 
core binding site sequence was able to somewhat compete with the labeled non-mutated oligo 
for HNF4α binding. The intensity of the band is reduced by about 50 % with addition of 100-
fold higher amount of mutated oligo. The core sequence is generally necessary for TF 
binding, and in this case the mutation only exchanged 4 of the 6 core bases. This, coupled 
with the near-perfect overall score of the predicted binding sequence could be the reason for 
the remaining low binding affinity. To prevent this binding in possible future experiments, 
the entire core sequence should be mutated. It can still be concluded that HNF4α binds 
47 
 
 
specifically to the YAP1 DRE sequence, and that the core sequence is responsible for most of 
the affinity. 
 
In the EMSA using the oligo with both an HNF4α and a CDX2-2 site, it was expected that 
both TF’s would bind to the oligo as they did in the previous EMSA’s. Because the sites are 
very close and partly overlap in the binding sequence it was unknown whether the TF’s would 
perhaps compete for binding or be able to bind simultaneously. The EMSA revealed that both 
HNF4α and CDX2 could bind to the oligo as expected, figure 19. Furthermore it was not 
possible to detect a band containing both TF’s and the probe. This suggests that only one TF 
binds to the oligo at a time, and that no simultaneously binding occurs. It would be 
interesting to investigate the hypothesis of CDX2 and HNF4α competition in this assay 
further. One way to do this could be by adding purified HNF4α or CDX2 protein to wells 
with supershifts to see if they could disrupt oligo-TF binding of each other. 
 
5.3 Functional effects of CDX2 and HNF4α on YAP1 constructs 
It has now been established that CDX2 and HNF4α bind to the DRE sequence in YAP1 and 
that CDX2 binds to the YAP1 promoter sequence along with an unidentified protein. Whether 
HNF4α binds to the YAP1 promoter is unclear. YAP1 promoter plasmids were constructed to 
test the effects of CDX2 and HNF4α on the regulation of YAP1. These were first transfected 
into Caco-2 cells to assess their endogenous transcription levels before further functional 
studies. In light of the binding site analysis, it was likely that the YAP1 promoter would be 
active in Caco-2 cells, and that the DRE would have an effect on the reporter gene expression 
level. A 10-fold increase was found in the transcriptional levels of the pGL4.10-YAP1 
promoter construct compared to the pGL4.10 background, figure 20. pGL4.10 is known to 
have a few weak CDX2 binding sites enhancing its transcription, but the 10-fold difference 
from this background transcriptional level clearly shows that the YAP1 promoter is active in 
Caco-2 cells. A 12-fold increase in the transcriptional level was also observed in the 
construct with the YAP1 DRE sequence inserted. This suggests that the DRE is a potent 
enhancer of YAP1 expression in Caco-2 cells. This also correlates with the strong binding 
sites found in the DRE. This identified the DRE as a novel and potent enhancer in Caco-2 
cells. 
5.3.1 Overexpression assay 
It was hypothesized that both HNF4α and CDX2 would be involved in the transcriptional 
regulation of YAP1 due to the newly discovered binding sites. Additionally, if the TF’s are 
the main regulators of YAP1 significant differences would be apparent when changing their 
concentration. Overexpressing CDX2 more than doubled the transcriptional activity of the 
construct with the YAP1 promoter to 10-fold more than its background, while HNF4α 
overexpression had no effect. This indicates CDX2 as an activator in the promoter region and 
supports the hypothesis that HNF4α might not bind to the YAP1 promoter at all.  
CDX2 seems to have the opposite effect on the expression of the DRE construct, by reducing 
it with more than 50 %. This suggests that CDX has a repressor activity on the enhancer at 
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the same time as having an activating effect on the promoter. CDX2 has generally been 
shown to activate and enhance gene expression but this result suggests that it might also 
function as a repressor. Only a few other studies have found evidence that CDX2 has a 
repressor role, but more studies have been emerging recently. Boyd et al. found that CDX2 
was bound to the promoter of cyclin- dependent kinase inhibitor2D, a kinase that inhibits cell 
cycle progression through the G1 phase. They discovered that CDX2 was bound to its 
promoter early in the differentiation process of Caco-2 cells and that increase in CDX2 
concentration decreased expression of the kinase (Boyd et al., 2010).  Another study found 
that CDX2 binds to a regulatory region of the Oct4 gene during the blastocyst development in 
mice. The binding of CDX2 repressed specific Oct4 expression and differentiation patterns 
partly by recruiting a repressive epigenetic modulator to the Oct4 gene (K. Wang et al., 
2010). These studies show that CDX2 can have repressor functionality. This supports the 
hypothesis that it might also be able to repress YAP1 expression through the DRE. 
 
Currently it is not possible to discern to what degree the change in expression from the 
overexpression assay is a result of direct or indirect regulation by CDX2 and HNF4α.  
Overexpression might cause unknown secondary effects apart from the increase of direct 
protein interaction with the YAP1 gene.  
The overexpression assay was conducted with cells already endogenously expressing the 
proteins. This makes it even more difficult to estimate the actual change in protein levels 
from overexpression. This is especially true for cells where the protein concentration changes 
during the experiment. An overload of protein might lead to secondary off-target effects by 
exhausting co-factors or by interacting with unknown molecules. In Caco-2 cells CDX2 and 
HNF4α regulate each other and both are part of a larger transcription factor network. This 
regulation is most likely affected by overexpression of either CDX2 or HNF4α, which in turn 
might inadvertently affect the concentration of each other and their TF partners. For future 
overexpression experiments it could be advantageous to use western blotting to quantify 
protein level and thus be able to measure the direct effect of transfecting the overexpression 
plasmids. 
Because CDX2 is an intestinal specific TF it was hypothesized that the regulation exerted by 
it on YAP1 might be specific to the intestinal cells. To test this hypothesis the YAP1 reporter 
constructs was transfected into HEK293 cells. HEK293 cells do endogenously express a small 
amount of HNF4α, but not of CDX2. A similar transfection setup was used by Furumiya et al. 
in which they co-transfected HEK293 cells with CDX2 and HNF4α CMV-pgl4.10 luciferase 
reporter plasmids containing Proton-coupled folate transporter, an intestinal folate uptake 
protein. This experiment showed that the expression of the reporter plasmid was upregulated 
by HNF4α expression and that this effect was attenuated by CDX2 expression (Furumiya, 
Inoue, Ohta, Hayashi, & Yuasa, 2013). This shows that CDX2 and HNF4α can function as 
regulators of other intestinal genes in the non-intestinal HEK293 cells. The transcription of 
the YAP1 promoter and DRE constructs in HEK293 cells was very low, and overexpressing 
CDX2 or HNF4α did not influence transcription patterns. This suggests that the regulation of 
CDX2 and HNF4α of the YAP1 construct might be specific to Caco-2 or perhaps intestinal 
49 
 
 
cells. It would be interesting to test the expression pattern of the YAP1 reporter constructs in 
other colon cell lines, such as SW480 to try and identify the extent of the specificity.  
 
5.3.2 Reporter constructs with mutated binding sites reveal specific regulation 
The overexpression experiment led us to the hypothesis that CDX2 might function as a 
repressor of the YAP1 DRE construct and that HNF4α is a potent activator. It was not clear to 
what extend these functions was a direct result of binding to the identified TFBS’s in YAP1 or 
resulted from indirect effects. To elaborate on this, YAP1-promoter-DRE reporter constructs 
was created whith the core binding sites of the TFBS’s replaced by a restriction site as in the 
EMSA oligos, figure 16. Transfecting Caco-2 cells should show an increased transcriptional 
activity of constructs with mutated CDX2 binding sites and a decrease of expression of 
constructs with HNF4α binding site mutations. Contrary to this expectation the transcriptional 
activity of all constructs was significantly decreased. The activity of the construct with the 
first CDX2 site mutated was strongly inhibited to a level only 2-fold above the promoter 
construct. The transcriptional level of this construct was about half of the YAP1-promoter-
DRE construct when CDX2 was overexpressed, figure 21. This finding contradicts the 
hypothesis of CDX2 as a repressor, and suggests that binding of CDX2 to both the first and 
second binding site in the YAP1 DRE activates transcription. The two assays together, 
indicates that an abundance of cellular CDX2 might overall repress YAP1 expression, but that 
it simultaneously is an important activator when interacting with the first CDX2 site in the 
DRE sequence. 
It is unclear what mechanism causes this regulation, but one explanation could be that the 
overexpression of CDX2 might repress other activators that contribute more to the overall 
activation than CDX2 binding to site 1. These other activators would have to target either the 
specific sequence of the DRE construct, or the general transcriptional system. It is possible 
that mutating the CDX2-1 site caused other TF to lose binding affinity as well. In fact, the 
EMSA with the first CDX2 site contained one additional protein from Caco-2 cells that did 
bind to the CDX2-1 site and for which the core sequence was important, figure 17. This 
means that the resulting effects from mutating the CDX2-1 site also affect at least one other 
protein which binds to YAP1. Therefore the effect cannot be attributed to CDX2 alone. It 
would be interesting to identify the unknown protein, as it might have an important role in 
YAP1 expression regulation. At this time it is thus unclear to what extend CDX2 is 
responsible for the repression of activity from mutating the CDX2-1 site. 
Because mutating either of the CDX2 sites reduced activity, it would be interesting to do a 
mutational study where both sites were mutated simultaneously. This could help demonstrate 
how much the direct binding of CDX2 in the DRE contributes to the observed regulation 
patterns. 
 
The activity of the construct with mutated HNF4α binding site was as expected lower, 
indicating that HNF4α might activate expression of YAP1 by binding to the identified binding 
site in the DRE. It was expected that a more prominent effect of HNF4α site removal would 
be evident, because of its strong activating effect identified in the overexpression assay. 
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Mutating the HNF4α site causes a decrease of about 40 % in activation level of the DRE 
construct, which is only slightly more than mutating the second CDX2 site is. This indicates 
that the enhancing effect of the DRE construct only partly is mediated by HNF4α binding to 
the HNF4α site. To cause the significant increase in transcription, noticeable in the 
overexpression assay, HNF4α might therefore exert a substantial indirect regulation apart 
from the direct binding alone. It is possible that HNF4α binding could have a stronger 
activating effect when expressed over a certain threshold than it would in endogenous 
amounts. It would be interesting to perform an overexpression of HNF4α in cells transfected 
with the DRE construct with mutated HNF4α site. This would possibly elucidate how much of 
the effect exerted by HNF4α is indirect.  
The activity of the double mutant was only slightly lower than each site mutation alone. If the 
transcriptional activity of the DRE construct was only influenced by direct interaction with 
CDX2 and HNF4α, the change in activity of mutating both sites would be similar to the sum 
of the change in activity of mutating each site separately. If for example each site contributed 
40 % of the total DRE activity, the expected change in the double mutant construct would be 
80 %. Because this is not observed some of the regulation is most likely indirect. 
 
It has been established that that both CDX2 and HNF4α and most likely also other TF’s take 
part in the regulation of the DRE. The importance of the three identified binding sites is 
evident in the mutational assay. Mutating the CDX2-1 site caused a reduction in DRE 
activation to double of the YAP1 construct without the DRE. Furthermore mutating the 
CDX2-2 and HNF4α site caused a 50 % reduction in activity. If these changes are combined 
the total enhancing effect of the DRE would be obliterated. If this effect is correct, it reveals 
that the three binding sites are essential for the enhancing effect of the DRE sequence. 
Unfortunately it was not possible due to time constraints, to investigate this effect by 
mutating all three sites simultaneously. 
 
5.3.3 Attempted knockdown of CDX2 and HNF4α 
The assays conducted so far have yielded some interesting results and have shown that CDX2 
and HNF4α both have direct and indirect regulatory effect on constructs containing the YAP1 
promoter and DRE sequences. The overexpression and mutational assays indicated CDX2 as 
an overall repressor of the YAP1 construct, but also as having an activating effect while 
bound to any of the three identified binding sites. Both assays indicate HNF4α as an activator 
of the YAP1 DRE construct. Assays meant to knock down CDX2 or HNF4α in Caco-2 cells 
was carried out to try to explain their role in this regulation in more detail, figure 24. After 
the CDX2 sh-RNA knockdown the amount of mRNA was measured for YAP1, CDX2, and the 
CDX2 target gene SI.  It was thought that knocking down CDX2 protein would cause an 
overall transcriptional activation of the YAP1 gene along with a decrease in transcription of 
SI. The knockdown assay did not show the expected result. It was not possible to detect a 
knockdown of the CDX2 mRNA while the SI mRNA level was decreased by over 80 %. There 
are several ways to interpret this result. SI is a standard target gene for CDX2 and it is 
unlikely that it would be decreased without CDX2 function or protein levels being impaired. 
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This could be explained by the idea that the sh-RNA succeeded in decreasing CDX2 protein 
levels, but that the assay did not show this. It is possible that the sh-RNAi instead of breaking 
down the CDX2 mRNA instead inhibited its translation. Since the assay was measuring only 
mRNA and not protein levels this hypothesis has not been validated. If it is true, it would 
mean that the effect seen on the assay of the YAP1 mRNA is the effect of CDX2 knockdown. 
However, if the mRNA levels accurately reflect the protein levels CDX2 was not knocked 
down. The decrease in SI mRNA is then caused by an unknown effect of the CDX2 sh-RNAi 
that is not exhibited by the scrambled sh-RNA.  
If it is assume that the assay fails to show the accurate protein level of CDX2 and that CDX2 
is in fact knocked down as the SI levels suggest, then the change in YAP1 expression should 
be analyzed. The change in YAP1 expression was not statistical significant, but showed a 
tendency to increase slightly. Because the level of CDX2 knockdown is unknown it cannot be 
determined how the concentration of CDX2 affects YAP1 concentration. It is important to 
know the level of CDX2 knockdown to evaluate if the corresponding change in the YAP1 
concentration is a result of it. A study using a similar approach to sh-RNAi knockdown found 
that they could reduce the CDX2 level in Caco-2 cells over 5 days, with a maximum of 45 %, 
50 %, and 70 % using three different RNAi constructs (Natoli, Christensen, El-Gebali, 
Felsani, & Anderle, 2013). Even if the experiment performed in this thesis could achieve this 
degree of knockdown it might not be sufficient to show a significant change in YAP1 protein 
level. Caco-2 cells containing 30 % - 55 % of their endogenic CDX2 might still be able to 
maintain basic transcriptional levels of YAP1.  
It is difficult to reach any conclusion from the knockdown assay about the effect of CDX2 on 
the expression of YAP1. There is a tendency for increased YAP1 expression if it is assumed 
that the knockdown of CDX2 worked on a protein level but not on an mRNA level. If the 
YAP1 expression is increased by knockdown of CDX2, it adds evidence for CDX2 as an 
overall repressor of YAP1 expression. This would be a novel and rare function of CDX2 and 
would add to the notion of CDX2 as a tumor suppressor. 
 
5.3.4 Connecting the Hippo pathway to CDX2 and HNF4α through YAP1 
The identified novel CDX2 and HNF4α binding sites in the YAP1 gene has a regulatory effect 
on YAP1 expression in Caco-2 cells. This finding directly links the Hippo pathway to the 
intestinal regululatory network of TF’s which includes CDX2 and HNF4α. However, the 
experimental data of this thesis also suggests that both CDX2 and HNF4α can regulate YAP1 
expression through indirect mechanisms. This indirect regulation might be partly or fully 
explained by the interaction and cross-regulation between CDX2 and HNF4α, and several 
TF’s which also regulate YAP1 expression.  
One model linking YAP1 and the CDX2 and HNF4α TF network could involve the 
transcription factor EP300. EP300 is involved in both basal gene transcription and as a co-
factor in DNA damage repair. It is intrinsically involved in the developmental regulatory 
network by binding to AP-1, CDX2, HNF1A, and Smads (Ban et al., 2002; Hussain & 
Habener, 1999; Nishihara, Hanai, Imamura, Miyazono, & Kawabata, 1999). AP-1 is not a 
single protein, but a group of TFs with shared functionality that regulates expression of genes 
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responsible for cell differentiation, proliferation, tumorigenesis, and apoptosis. AP-1 is 
generally comprised of TFs from the JUN and FOS family, reviewed in (Hess, Angel, & 
Schorpp-Kistner, 2004). AP-1 and EP300 is connected through JUND and FOSL2 and can 
also form a complex with the TF USF-1, figure 25 A. EP300 interacts with most of the TF’s 
discussed in this thesis and also appears on the Caco-2 ChIP-seq data for both the YAP1 
promoter and DRE, figure 12 and figure 13. The ChIP-seq data also reveals likely binding 
sites for CDX2, HNF4α, JUND, FOSL2 and USF-1 in YAP1 (Rosenbloom et al., 2013). 
This leads to a possible model where CDX2 and HNF4α can regulate YAP1 expression by 
binding to its promoter and DRE but also by indirect effects through affecting EP300 and its 
co-factors. This model also includes a possible feedback mechanism by which the YAP1 
protein could possibly affect the regulation of EP300 by affecting its binding to Smads 
through protein-protein interactions, figure 25.  
 
 
Figure 25 – model of the interactions between the intestinal developmental regulators CDX2 and HNF4α and the 
Hippo pathway through the regulation of YAP1 expression and direct protein-protein interactions with EP300. 
Known interactions between TF’s are marked with arrows. Black color is used for protein-protein interactions 
while red color indicates a transcriptional regulation. A) The TF’s FOSL2, JUND, USF-1, and EP300 can interact 
with each other and EP300 can interact with Smads, CDX2 and HNF1. B) Transcriptional regulators control the 
expression of YAP1 by binding to its promoter or DRE or by indirect regulation. Both CDX2 and HNF4α bind and 
regulate the YAP1 gene, but the regulation mechanism by the USF-1, FOSL2, JUND, EP300 network is unknown. 
The YAP1 protein interacts with Smads. C) CDX2, HNF4α, and HNF1 regulate each others expression. CDX2 and 
HNF1 can interact with each other and both can bind to EP300.  
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5.4 The effect of YAP1 regulation by CDX2 and HNF4α 
The results of this thesis reveal a novel transcriptional regulation of the Hippo pathway 
effector YAP1 by the transcription factors CDX2 and HNF4α. The DRE has been identified 
as an enhancer of YAP1 expression and its activity might be specific to intestinal cells. The 
overexpression assays suggests that CDX2 represses the enhancer effect and that HNF4α adds 
to the enhancing effect. A significant change in YAP1 expression would most likely influence 
the developmental patterns of both intestinal development and tumorigenesis. 
 
The DRE up-regulates YAP1 expression about 12-fold with endogenous levels of TF’s present 
in Caco-2 cells. The DRE might thus be important in determing the concentration of YAP1 
protein available in intestinal cells. This expression level is significantly increased by 
overexpression of HNF4α. Increased expression leads to an increase of cytosolic YAP1 
protein. In the cytosol YAP1 can interact with Smads and inhibits their entry into the nucleus 
(Attisano & Wrana, 2013). One key function of the Smads is to induce apoptosis on signaling 
from the TGF-β pathway (de Caestecker, Piek, & Roberts, 2000). An increased cytosolic 
YAP1 concentration facilitated by the effect of HNF4α on the DRE might therefore inhibit 
apoptosis and allow for tumor progression. Because CDX2 seems to repress the YAP1 
expression it might have the reverse effect and facilitate Smad induced apoptosis. However, 
cytosolic YAP1 can also block the expression of proliferative WNT specific target genes by 
interacting with β-catenin and preventing its transport to the nucleus. WNT target genes is as 
mentioned involved in cell proliferation. A cytosolic YAP1 increase thus seems to inhibit 
both proliferation and apoptosis. 
 
The main function of YAP1 is exerted by its transcriptional regulation, which is facilitated by 
its transport to the nucleus. An increased nuclear YAP1 concentration has been linked to 
development of tumors and metastasis. This is partly due to the proliferative effect of YAP1 
target genes. An increased nuclear YAP1 concentration can also overcome the normal cell-
cell contact inhibition necessary for tumor growth (Zhao et al., 2007). However, an increased 
YAP1 expression was also shown to facilitate apoptosis in the event of DNA damage by 
upregulating P73 (Strano et al., 2001). 
Because YAP1 interacts with several pathways and confers both transcriptional and direct 
regulation it is likely that its own expression needs to be tightly controlled to enable 
homeostasis and correct cell development. This control would possible be specific to tissues 
and differentiation levels of the cells. The enhancing effect of the DRE is possibly intestinal 
specific. This suggests that intestinal specific TF’s and possibly co-factors are responsible for 
the transcriptional activity conferred by the DRE. CDX2 and HNF4α have been shown to 
regulate the expression of YAP1 through the DRE, but according to the mutational assay, their 
main effect does not seem to be mediated by their direct interaction with the DRE. It has not 
been possible to identify how they exert their indirect effects but it is likely that it involves 
the regulation of other TF’s. This would mediate intestinal specificity in two ways; since 
CDX2 is intestinal specific and HNF4α is limited to few other tissue types the regulatory 
network they are part of can mediate intestinal specific regulation. They could possibly up- or 
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down-regulate the expression of other general important YAP1 regulators that interact with 
the DRE. This could be EP300 as suggested, any of its partners, or a number of unidentified 
TF’s. A second type of specificity can be mediated by the interaction of CDX2 and HNF4α 
with the newly discovered binding sites in the DRE. Thus a model is proposed where the 
regulation by CDX2 and HNF4α on the YAP1 expression is two-fold, figure 26. 
 
 
Figure 26 – proposed model for a direct and an indirect transcriptional regulation of YAP1 by CDX2 and HNF4α. 
CDX2 and HNF4α up-regulates YAP1 expression by direct interaction with the DRE (blue arrows). They also 
might regulate unknown TF’s that either represses (for CDX2) or activates (for HNF4α) the YAP1 expression. 
YAP1 is expressed and inhibits TGF-β and WNT signaling by blocking nuclear entry of Smads and β-catenin 
respectively, by sequestering them in the cytosol.  
The proposed models of how CDX2 and HNF4α interact with other TF’s and pathways to 
regulate YAP1 expression add new layers of complexity to the regulation of cell proliferation 
and differentiation.  It becomes more evident that many TF’s work together to regulate the 
expression of YAP1. The complexity of its regulation shows the importance of controlling 
YAP1 expression in the cellular environment. The idea of YAP1, CDX2, or HNF4α as simple 
tumor suppressors or oncogenes is oversimplified as they are connected by regulatory 
networks to each other and each has many functions. The overexpression data indicates that 
CDX2 might exert an overall tumorsuppressor activity in intestinal cells by repressing YAP1 
expression. They also indicate that HNF4α has oncogenic properties in its ability to greatly 
increase the enhancer effect of the DRE by both interacting with the newly discovered 
binding site and by an unknown indirect regulation. 
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6 Concluding remarks 
A novel enhancer was discovered in the human YAP1 gene. The enhancer is 600bp and 
located at pos (+73030 to +73630) relative to the TSS of the YAP1 gene. In the human 
colorectal cancer cell line Caco-2, insertion of the enhancer into luciferase reporter constructs 
carrying the YAP1 promoter increased expression 12-fold. The TF HNF4α increased the 
enchancers effect 3-fold, suggesting an oncogenic potential. The intestinal specific TF CDX2 
attenuated the enhancer effect by about 50 %, suggesting it has a tumor suppressor role. 
Transfections with reporter plasmids showed no activity in HEK293 cells, indicating that the 
enhancer might be specifically used in intestinal cells. 
Three novel binding sites were discovered in the enhancer, two CDX2 binding sites and one 
HNF4α site. Transfections with reporter plasmids with mutated binding sites showed that 
binding of CDX2 and HNF4α to these sites was important for the effect of the enhancer. 
 
The discovery of an enhancer in YAP1 that is regulated both directly and indirectly by CDX2 
and HNF4α defines a novel connection between the growth inhibitory Hippo pathway and the 
instestinal regulatory TF network. This previously unknown connection might be a specific 
method for intestinal cells to regulate YAP1 and thereby proliferation and differentiation 
patterns.These results assists in increasing the understanding of the complex integration of 
signals from different TF’s and networks in regulation of cell proliferation and tumorigenesis 
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8 Appendices 
8.1 Appendix I – Full size EMSA images 
 
Figure 27 – Full size image of the EMSA containing the CDX2-1 probe. 
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Figure 28 - Full size image of the EMSA containing the CDX2-2 probe. 
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Figure 29 - Full size image of the EMSA containing the HNF4α probe. 
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Figure 30 - Full size image of the EMSA containing the CDX2-2+HNF4α probe. 
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8.2 Appendix II - YAP1 protein sequence 
 
 
Figure 31 – Isoform 1 of the 504 aa long isoform of the YAP1 protein (gi|23398532). The colored amino acids are 
motifs where the serine is targets for phosphorylation by the LATS kinase. The strikethrough text annotates the 
amino acids that are missing in isoform 2 which is the other commonly used isoform of YAP1.  
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8.3 Appendix III - List of abbreviations 
αE-catenin  α epithelial catenin 
β-TRCP   β–Transducin repeat-containing proteins 
AP-1   Activating protein 1 
CEBP   CCAAT/enhancer binding protein (C/EBP), beta 
CBCC   Crypt based columnar cells 
CDX2    Caudal type homeobox 2 
Caco-2  Human colon adenocarcinoma cells  
ChIP   Chromatin immunoprecipitation 
CRC    Colorectal cancers 
CREBBP   CREB binding protein 
DRE    Downstream regulatory element 
ECM    Extracellular matrix 
EGFR-4  Epidermal growth factor receptor 4 
EMSA  Electrophoretic mobility shift assay 
ENCODE   Encyclopedia of DNA Elements 
EP300/P300   E1A binding protein p300 
FOSL2  FOS-like antigen 2 
H3K27Ac   Histone 3 lysine 27 acetylation 
HEK293  Human Embryonic Kidney 293cells 
HNF1   Hepatocyte nuclear factor 1 
HNF4α   Hepatocyte nuclear factor 4 alpha 
JUND   Jun D proto-oncogene 
LATS1/LATS2 Large tumor suppressor kinase 1/2 
MAPK   Mitogen-activated protein kinase 
MOB1  MOB kinase activator 1 
MST1/MST2 Mammalian Ste20-like protein kinases ½ 
Myb    v-myb avian myeloblastosis viral oncogene homolog 
NCID   Notch intracellular domain 
NF2    Neurofibromin 2 (merlin) 
PDZ    Post-synaptic density, Discs large, Zonula occludens-1 
qPCR   Quantitative polymerase chain reaction 
SH3   Src homology 3 domain 
sh-RNAi  Short hairpin RNA interference 
SI    Sucrase Isomaltase 
TAZ/WWTR1 Transcriptional co-activator with PDZ-binding motif 
TEAD   Transcription factor TEA domain family member  
TF    Transcription factor  
TFBS    Transcription factor binding site  
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USF-1  Upstream transcription factor 1 
WWC1  WW and C2 domain containing 1 
YAP1    Yes-associated protein 1 
